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Summary 
 
In the late 1990‟s a disturbing trend of geographically distinct melarsoprol 
treatment failures accompanied a dramatic resurgence of Human African 
Trypanosomiasis. These studies present results from a sentinel surveillance 
network (HATSENTINEL) that was established at nine sites in five countries 
in response to this crisis, recommendations on the need for continued 
trypanosome specimen collection and a call for pharmacovigilance. 
Seven sites are located in Democratic Republic of the Congo (DRC), Angola, 
or Sudan, where T. b. gambiense is endemic and two sites are located in 
Uganda and Tanzania, areas endemic for T. b. rhodesiense.  The facilities 
included health centers and hospitals operated by ministries of health and 
nongovernmental organizations. The HATSENTINEL network addressed the 
lack of standard diagnostic and treatment protocols used for HAT in African 
facilities by using a standardized form to collect data about the specific 
diagnostic methods and treatment regimens in use at the sentinel facilities.  
  
The melarsoprol failure rates detected by HATSENTINEL in northern 
Angola (98%) and in East Kasai Province of DRC (61%) are substantially 
higher than previously reported. There was no evidence of geographic spread 
of melarsoprol-refractory infection.   The drug remained effective at a site in 
DRC during the 6 years of surveillance, despite its proximity to the northern 
Angola site. 
The failure rates did prompt the MOHs to switch protocols to an alternative 
drug, eflornithine. The four centers that used eflornithine as first line 
treatment for Stage II patients had failure rates ranging from 2.3% to 3.9%; 
this led to overall reductions in the number of cases. 
The study attempted to isolate and investigate parasite strains resistant to 
melarsoprol but the limited results did not find this to be the case. The 
investigation for resistant strains should continue. 
The results from the HATSENTINEL network has reinforced the need for 
continued sentinel surveillance. This has also revealed the need for improved 
pharmacovigilance. There will be many barriers to establishing a reliable 
pharmacovigilance network, yet these challenges do not mean that 
pharmacovigilance is not possible in Africa or should be set to a lower 
standard. In the case of human African trypanosomiasis we argue that the 
most rigorous approaches advocated by WHO should be embraced. 
 
 8 
Zusammenfassung 
Der drastische Wiederanstieg der Fallzahl der afrikanischen Schlafkrankheit 
gegen Ende der Neunzigerjahre war begleitet von einer beunruhigenden 
Tendenz einer geographisch begrenzten Zunahme von Rückfällen nach 
Melarsoprol - Behandlung. In der vorliegenden Arbeit sind die Resultate, 
welche im Rahmen eines Überwachungnetzwerks  (HATSENTINEL) 
erhoben wurden zusammengefasst. Das Netzwerk wurde als Antwort auf 
diese Krise in neun Behandlungszentren in fünf Ländern eingerichtet und hat 
zum Ziel Empfehlungen zur Arzneimittelüberwachung zu erarbeiten und eine 
Sammlung von Proben zur wissenschaftlichen Untersuchung zu erstellen. 
Sieben der beteiligten Zentren befinden sich in der Demokratischen Republik 
Kongo (DRK), in Angola und in Sudan, wo T.b. gambiense gehäuft 
vorkommt und zwei in Uganda und in Tansania wo die Schlafkrankheit durch 
T.b. rhodesiense verursacht wird. Die beteiligten Behandlungszentren 
umfassen lokale Gesundheitszentren (Polykliniken) sowie Krankenhäuser, 
welche durch Gesundheitsministerien, Nichtregierungsorganisationen und 
katholische Missionen geführt werden. Das HATSENTINEL Netz 
untersuchte die Problematik der fehlenden Standardprotokolle für die 
Diagnostik und die Behandlung der Krankheit. Um dieses Ziel zu erreichen, 
wurde ein standardisiertes Formular verwendet, um Daten über die 
jeweiligen Diagnosemethoden und die Behandlungsschemata zu sammeln, 
welche in den entsprechenden Zentren zum Einsatz gelangen.  
 
Die Melarsoprol - Rückfallquote, die durch HATSENTINEL in Nordangola 
(98%) und in der Ost-Kasai Provinz von DRK (61%) ermittelt wurden sind 
wesentlich höher als vorher berichtet. Hingegen gab es keinen Hinweis auf 
eine geographische Verbreitung der Melarsoprol-refraktären Infektion. Das 
Medikament blieb an einem Zentrum in der DRK während der 6 Jahre der 
Überwachung trotz seiner Nähe zum Nordangola-Zentrum mit der höchsten 
Rückfallrate wirkungsvoll. 
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Die Rückfallraten veranlassten die Gesundheitsministerien, die Behandlung 
auf das alternative Medikament Eflornithin umzustellen. In den vier Zentren, 
welche Eflornithin für die Behandlung der Zweitstadiumspatienten zuerst 
verwendeten, wurden Rückfallrate von 2.3% bis 3.9% beobachtet, was zur 
Reduktion der gesamten Fallzahl beitrug. 
Im Rahmen der Studie wurde versucht, Parasiten zu isolieren, um deren 
Melarsoprol - Resistenz zu analysieren, was aber in der begrenzten Anzahl 
der isolierten Stämme nicht der Fall war. Die Untersuchungen über resistente 
Parasitenstämme werden fortgesetzt werden.  
Die Resultate des HATSENTINEL Netzwerks unterstrichen die 
Notwendigkeit einer gezielten und anhaltenden Überwachung der 
Medikamentenresistenz (Surveillance) und hat auch den Bedarf für eine 
verbesserte generelle Arzneimittelüberwachung aufgezeigt 
(Pharmacovigilance). Um dies zu erreichen werden noch viele Hürden 
überwunden werden müssen, aber die bestehenden Schwierigkeiten bedeuten 
nicht, dass Pharmakovigilanz in Afrika nicht oder nur bedingt möglich ist. Im 
Falle der menschlichen afrikanischen Schlafkrankheit (Trypanosomiasis) 
sind wir der Meinung, dass der rigoroseste Ansatz, welcher von der 
Weltgesundheitsorganisation WHO empfohlen wird, angewendet werden 
sollte. 
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Chapter 1 
 
General information on HAT and current epidemiology 
 
Literature review and background 
 
Human African Trypanosomiasis (HAT) is a parasitic disease transmitted 
through the bite of the tsetse fly (Glossina ssp.) and is found in 36 countries 
in sub-Saharan Africa (Fevre, Picozzi et al. 2006; Maudlin 2006). It was a 
major public health problem for the first half of the 20
th
 century. Intensive 
control programs reduced the disease to fewer than five thousand cases 
annually by the 1960‟s, the majority of which were T.b. rhodesiense. 
However in the past two decades there was a resurgence of disease. This 
reemergence was due predominantly to cases of T.b. gambiense in central 
Africa (Van Nieuwenhove, Betu-Ku-Mesu et al. 2001). There has also been 
an increase of cases of T.b. rhodesiense in Tanzania and into new areas of 
Uganda but these make up less than 5% of the total(Simarro, Franco et al. 
2006). Despite a historical presence, there has been no increase of cases 
noted in West Africa. The increase in cases was most evident in Angola, DR 
Congo and Sudan (Moore, Richer et al. 1999; Lutumba, Robays et al. 2005), 
countries that have all been suffering from conflict and war. In 1995 WHO 
issued a statement declaring that over 25,000 new cases were being reported 
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per year but that was due to inadequate surveillance the annual number of 
newly acquired infections was estimated to be between 300,000 and 500,000.  
This was a dramatic increase from the levels reported in the 1960‟s and was a 
reminder that when ignored this disease could reach epidemic levels. The 
disease had been controlled in the past and had been considered to no longer 
be a public health problem. The levels reported in 1995 therefore were 
shocking to many and exposed many issues that had led to the resurgence. It 
became evident that there was inadequate surveillance (Cattand, Jannin et al. 
2001), that there was a lack of funding for case detection, and that the 
elevated cost of the drugs for treatment often lead to a lack of availability.  
There has been an improvement since 1995 due to more resources being 
made available for control of the disease and the donations of drugs to WHO 
in 2001(Jannin and Cattand 2004; Jannin 2005). In the period from 1997 to 
2004 the number of people screened has increased from 1,345,000 to 
3,300,000 while the number of new infections reported has dropped from 
37,000 to 17,000 (WHO 2006). 
This reduction has led WHO to declare that the elimination of T.b. gambiense 
is feasible. A goal has been set for elimination by 2015. The African Union 
has an even greater target of eradicating the African continent of both T.b. 
gambiense and T.b. rhodesiense (Kabayo 2004). 
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Control Methods 
 
There are two main approaches for control, the reduction of the disease 
reservoir and vector control. T.b. rhodesiense is a zoonosis and therefore 
control efforts focus on the vector. Epidemiologically, man is the most 
important reservoir for HAT disease from T.b. gambiense (Leak 1999). The 
reduction of the reservoir has been the cornerstone of control and has been 
proven effective when used alone or combined with vector control.  
The disease is spread by the bite of a tsetse fly that has previously taken a 
blood meal from an infected host (Leak 1999). Active case detection (ACD) 
in the known foci allows for the identification of T.b. gambiense infected 
individuals that are serving as reservoirs (Chappuis, Loutan et al. 2005). The 
primary method for ACD is the use of mobile teams of examiners who move 
from community to community in search of infected individuals (Robays, 
Bilengue et al. 2004). The mobile teams have increased their ability to do 
mass screening of populations with an antibody assay, the card agglutination 
trypanosomiasis test (CATT)(Chappuis, Loutan et al. 2005) (Inojosa, 
Augusto et al. 2006). This is not a test that can provide definitive diagnosis 
but allows for the identification of suspected cases. Individuals identified by 
the CATT will have additional testing to determine if they are infected with 
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the disease, and if so, at what stage(Lejon and Buscher 2001). The primary 
method for determining disease stage is through an examination of the 
CSF(Lejon and Buscher 2001).    
There are also effective methods for the control of the vector with the use of 
fly traps that can be maintained by the local populations. Vector control can 
help reduce disease but without treatment of sick people disease, elimination 
is not possible (Cattand 2006) as humans are the primary reservoir for 
T.b.gambiense(Burri and Brun 2003). 
The key factors to address if a disease can potentially be controlled or 
eliminated are the biologic and technical feasibility, the costs and benefits, 
and the societal and political considerations (Cattand 2006). The current 
arguments for T.b. gambiense HAT elimination include:  the current 
improved political will (WHO and AU statements); new cost estimates that 
show the costs associated with control are lower than previously assumed and 
the benefits are higher; better access to patients in geographic regions 
previously cut-off due to conflict; and greater availability of treatment drugs 
through donation programs(Robays, Lefevre et al. 2007; Robays, Raguenaud 
et al. 2008). Access to effective chemotherapy is important even if 
elimination is not realistic, as it is a key factor for any HAT control 
program(Simarro, Jannin et al. 2008).  
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If T.b. gambiense elimination is implemented, a monitoring and evaluation 
plan is needed to continuously track the success or failure of control and 
elimination activities (Bouchet, Legros et al. 1998; Cattand, Jannin et al. 
2001). It will be helpful in setting objectives rationally and in choosing 
appropriate indicators of progress. M&E tools are a critical component of 
ongoing elimination campaigns for other tropical disease, e.g. onchocerciasis 
and lymphatic filariasis (WHO 2005).  
Treatment 
 
Effective treatment is a key element of disease control for T.b. gambiense, as 
noted above. The treatment of infected individuals is vital as HAT is fatal 
when left untreated. Humans are the primary reservoir for T.b. gambiense 
associated HAT and therefore effectively identifying and treating those 
infected will reduce the levels of disease (Leak 1999; Jannin and Cattand 
2004). This has been noted in foci where the disease has been eliminated 
such as Bioko Island (Simarro, Franco et al. 2006). 
There are two stages of the disease. Stage I disease is limited to the haemo-
lymphatic system with the trypanosomes circulating in the blood and lymph 
fluid(Lejon and Buscher 2001). Stage II disease is characterized by invasion 
of the central nervous system by the parasite(Fevre, Picozzi et al. 2006). 
Untreated HAT is fatal, and a substantial proportion of infected persons 
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remain undiagnosed and untreated(Odiit, Coleman et al. 2005).   Of those 
who ultimately receive treatment, the majority have central nervous system 
involvement (stage II disease) at the time of diagnosis(Checchi, Filipe et al. 
2008).   
Patients presenting with relapse after treatment for either stage I or stage II 
disease tend to have central nervous system involvement. 
There is a real lack of medication options with only four drugs currently 
licensed for treatment (Croft, Barrett et al. 2005). Pentamidine and suramin 
are the drugs used for treating Stage I(Croft, Barrett et al. 2005); pentamidine 
is the preferred drug to treat T.b. gambiense while suramin is used for T.b. 
rhodesiense(Pepin and Milord 1994). Pentamidine is less effective for T.b. 
rhodesiense and this is why suramin is used(Fevre, Picozzi et al. 2006). Since 
both pentamidine and suramin are unable to cross the blood-brain barrier, 
they are not effective for Stage II. Eflornithine and melarsoprol are licensed 
for Stage II disease though eflornithine is not effective against T.b. 
rhodesiense. This is due to the parasite not being susceptible to the 
compound because of the high ornithine decarboxylase turnover (Burri and 
Brun 2003). A nifurtimox-eflornithine combination therapy for Stage II T.b. 
gambiense is a promising option (Priotto, Kasparian et al. 2007), but the lack 
of treatment alternatives should be of dire concern (Moore 2005).   
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Melarsoprol was introduced in 1949(Friedheim 1974) and has been the 
primary drug used for stage II patients for the last fifty years. It is an arsenic 
derivative and is trypanocidal. The current treatment regimen for T.b. 
gambiense takes ten days of in-patient care(Schmid, Nkunku et al. 2004; 
Schmid, Richer et al. 2005), an improvement over the month long hospital 
stay previously required. Due to the toxicity of the drug there are adverse 
effects, the most severe being an encephalopathic reaction(Blum, Nkunku et 
al. 2001); skin reactions are also observed. Despite these concerns 
melarsoprol remained the first line drug of choice instead of eflornithine for 
most national control programs for several reasons. The primary factors 
against eflornithine were the frequent IV administration, the cost of infusion 
sets (now donated), concerns about sterile preparation of infusions and the 
risk of possible catheter site infections(Burri and Brun 2003).   
A mounting area of concern is the fact melarsoprol is showing evidence of 
reduced efficacy in certain foci (Brun, Schumacher et al. 2001; Ollivier and 
Legros 2001). Historically, melarsoprol efficacy (91-95%) had shown little 
change in 50 years of use. However, elevated rates of melarsoprol treatment 
failure were observed in foci with Angola, Sudan, and Uganda in the late 
1990s (Legros, Evans et al. 1999; Moore, Richer et al. 1999; Brun, 
Schumacher et al. 2001). The simultaneous appearance of treatment failure in 
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geographically distinct and widely separated areas was worrisome, 
particularly because treatment failure in most HAT-endemic areas were not 
being closely monitored and methodology for calculating failure rates was 
not standardized. Protocols between countries and centers were not standard 
and patient follow-up was often incomplete making the data difficult to 
interpret. The cause of the observed treatment failure is unclear. Potential 
causes include factors related to drug, factors related to host, and factors 
related to parasite (Burri and Keiser 2001).    
Several factors related to drug have been examined (Brun, Schumacher et al. 
2001). Less work has been done on factors related to host; however, no 
difference has been noted in drug pharmacokinetics between new patients 
and treatment failures (Burri and Keiser 2001). Limited data suggest HIV 
coinfection may play a role (Moore, AM personal communication) but is not 
likely to be the primary factor. Parasite drug resistance is suspected, but few 
isolates from patients have undergone drug susceptibility testing to date 
because of the technical difficulties in isolation, cryopreservation and study 
of the parasite (Likeufack, Brun et al. 2006). 
Melarsoprol resistance has been induced in laboratory isolates and is linked 
to the loss of an aminopurine transporter, P2, that mediates the uptake of the 
drug and of its metabolite, melarsen oxide (Carter and Fairlamb 1993; 
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Barrett, Zhang et al. 1995; Carter, Berger et al. 1995).  This laboratory 
resistance, along with the presence of melarsen oxide, has raised questions of 
whether the in vitro methods used previously are adequate for detecting 
melarsoprol resistance in field isolates.  
Alternative therapies to melarsoprol are being used. Eflornithine 
monotherapy has been the main alternative as it is less toxic than melarsoprol 
yet more difficult to administer. There are also some adverse events that can 
be of concern including anemia and leucopenia (Milord, Pepin et al. 1992).  
Eflornithine may be even more vulnerable to the development of resistance 
than the other drugs, which is why combination treatment options are 
evolving and it will be necessary to monitor new regimens that might become 
widespread such as eflornithine-nifurtimox combination therapy (Priotto, 
Fogg et al. 2006) (Bisser, N'Siesi et al. 2007) or any new compounds that 
become available. 
 
HATSENTINEL 
 
HATSENTINEL was created in order to establish sentinel surveillance for 
treatment failure and drug resistance in the affected countries. 
HATSENTINEL is currently WHO + CDC sponsored with STI, MOHs and 
NGO working partners. It currently includes nine sites in five countries. 
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There were four sites in DR Congo, two sites in Angola and one site in Sudan 
for T.b. gambiense. The sites in Uganda and Tanzania were for T.b. 
rhodesiense.   
Unlike most sentinel surveillance systems, which collect data for cases of 
treatment failure only, HATSENTINEL collected reports for all stage II 
patients. This approach provided denominator data and the ability to calculate 
actual rates of treatment failure. It also allowed denominator flexibility in the 
choice of case definitions for data analysis.  
Data collection began in July 2002. The collection was achieved with a 
standardized report form for all Stage II patients. Geographic, demographic, 
diagnostic and treatment information was collected. The report form 
ascertained if a patient was previously treated and what the current treatment 
regimen was, allowing for the pinpointing of problem areas. In addition to 
the patient report form, there was also a facility form that was used to collect 
information about each site, including the medications used, the treatment 
schedules, diagnostic methods and tests used, other medications used prior to 
treatment, number of beds, and number of patients seen each year at the time 
of site enrollment. The facility questionnaire allowed for differentiation 
between centers, something important for the surveillance since staging and 
diagnostic techniques and capabilities varied between sites. This allowed for 
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the magnitude and geographic distribution of treatment failure to be better 
defined. It is also provided a mechanism for obtaining and performing drug 
susceptibility testing of isolates. 
 21 
Chapter 2 
 
Rationale of the project: 
 
Monitoring temporal and geographic trends in treatment efficacy are needed 
not only for the selection of optimal first line therapy in specific areas 
endemic for HAT but also to provide timely data on refractory infection 
especially in view of the limited arsenal of chemotherapy.  
 
Specific Objectives:   
Collect and analyze data for HAT treatment failure risk factors to determine 
magnitude and geographic distribution of the problem. In sites where 
treatment failure is documented, collect specimens for drug susceptibility 
testing to determine if drug resistance is the cause of treatment failure.  
 
Study design 
 
Data were collected on all stage II patients seeking treatment at the selected 
sentinel surveillance sites. The patients were followed longitudinally. The 
collection was achieved with a standardized report form for all Stage II 
patients. A facility form collected information about each treatment site and 
their methods of diagnosis and treatment. There was also a mechanism for 
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obtaining and performing drug susceptibility testing of isolates. 
Cryopreservation of specimens was hampered by the low parasitemias in T b. 
gambiense infections and the fragility of the parasite. Reto Brun‟s group at 
STI developed a new preservation medium (Maina, Oberle et al. 2007) that 
was used. 
 
Study population 
 
The study registered and followed all stage II HAT patients from the sentinel 
sites.  The population was comprised of the local communities, groups that 
ranged from rural farmers and pastoralists to diamond miners. Men and 
women were enrolled as well as children.  HATSENTINEL collects case 
reports for all patients admitted to the participating facilities for treatment of 
infection with central nervous system involvement (stage II) and whose HAT 
diagnosis was made with a positive parasitological test (i.e., trypanosomes 
were observed in blood, lymph node aspirate, or cerebrospinal fluid (CSF)).  
Patients were included in the analysis if they fulfilled the following case 
definition for stage II infection:  parasites observed in CSF, and/or CSF white 
blood cell count (WBC) >5/μl.   After completing a treatment course, patients 
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are instructed to return for follow-up examinations of CSF every 6 months 
for 2 years.   
Human subjects issues 
 
This project was classified as surveillance (non-research) by the CDC IRB 
and, as such, is exempt from IRB review. Patients were followed 
prospectively by hospitals, but all data reported to the surveillance system 
and the specimens provided are without personal identifiers. Linkage data are 
not available to the surveillance system. 
 
Data analysis methods 
 
Analysis of the sentinel surveillance data was done using the EpiInfo and 
SAS computer programs. There was univariate and multivariate statistical 
analysis along with more advanced procedures such as logistic regressions 
and Kaplan-Meier survival analysis. Trends in treatment failure rates were 
examined by stratifying data by quarter of admission as well as using 
methods of survival analysis including the „survivor function‟ s(t) 
representing proportions of patients successfully treated after any given day t 
since treatment.  Treatment failure at any given day t is presented by the 
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inverse function 1 minus s(t). The statistical methods selected were made in 
consultation with CDC statisticians.  
Case definitions: 
 
Confirmed case: a case with direct demonstration of the parasite, 
compatible or not with clinical description. 
 
Stage 1 sleeping sickness: parasite seen in blood and/or lymph nodes, 
with CSF containing no detectable trypanosomes and a leukocyte count 
≤ 5/µl. 
 
Stage 2 sleeping sickness: CSF containing trypanosomes and /or 
leukocyte count       > 5/µl. 
 
Treatment failure, confirmed: any confirmed trypanosomiasis 
patient with trypanosomes observed microscopically in an 
examination of CSF, blood or lymph gland fluid during a two-year 
follow-up period after receiving a complete treatment regimen 
appropriate for the initially diagnosed disease stage. 
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Treatment failure, suspected*: a confirmed trypanosomiasis patient 
without direct demonstration of the parasite that is compatible with 
the clinical description and/or with a positive serology, during a 
two-year follow-up period after receiving a complete treatment 
regimen appropriate for the initially diagnosed disease stage. 
 
*Suspicion is based on the local risk of contracting the disease and 
local disease historical background. 
 
 
Surveillance in the past was challenging since determining accurate treatment 
failure rates are difficult because sites have been using different case 
definitions and denominators. Analysis was further complicated because 
there is not an effective test to show that a patient has been cured. Using a 
standard approach through HATSENTINEL provided a more accurate picture 
of treatment failure issues.  
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Specimen collection methods 
 
The HATSENTINEL cryopreservation protocol followed the methods 
developed by Dr. Reto Brun‟s lab at STI (Maina, Oberle et al. 2007). 
Samples of 2-3ml of venous blood was collected, concentrated in a centrifuge 
and re-suspended in Triladyl. The samples were then stored in a liquid 
nitrogen dry shipper until they were ready to be injected in rodents for 
amplification.  
 
Specimen testing for drug susceptibility 
 
In vitro drug susceptibility 
The collected specimens were to be tested using the cryopreserved parasites 
from the infected HAT patients. The methodology called for isolate 
propagation in susceptible rodents (Mastomys or SCID mice) and testing for 
drug susceptibility in with the following assay: incorporation of 
3
H-
hypoxanthine in culture at serial drug dilutions for measuring the IC50. Due to 
technical problems, in vitro testing was not successful. 
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In vivo drug susceptiblity 
Balb/c mice were used for the testing. The techniques developed in Reto 
Brun‟s lab were followed (Maina, Maina et al. 2007). The mice were 
immunosuppressed with 300 mg/kg bwt cyclophosphamide (Endoxan®) 48 
hours days prior to infection and on days 14 and 28 post infection. These 
specimens were used to infect mice intraperitoneally. The mice were then 
separated into three groups; one group of mice served as controls, another 
group received a melarsoprol dose for 4 days at 1 mg/kg, and a last group 
received a melarsoprol dose for 4 days at 4 mg/kg. Parasitemia was 
determined by examining tail blood on day 3, 7, 10, 14, 17, 21, 24, 28 and 
31.  
Pharmacovigilance 
 
Pharmacovigilance (PV) and pharmacoepidemiology (PE) is based in the 
monitoring of adverse events for drugs that have been approved and are 
being marketed(ISPE 2007). The World Health Organization has advocated 
for greater monitoring of medicinal products (WHO 2002) worldwide and in 
the dissertation pharmacovigilance will be defined as, “the science and 
activities relating to the detections, assessment, understanding and prevention 
of adverse effects or any other possible drug-related problems.” 
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Pharmacovigilance is a subset of pharmacoepidemiology, a field that applies 
“epidemiologic methods to pharmacological issues”(ISPE 2007).  
The dissertation will present the need for a pharmacovigilance approach to 
HAT treatment. 
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Abstract 
A limited number of drugs are available for treatment of human African 
trypanosomiasis.  Reports of reduced effectiveness of melarsoprol, which had 
long been a mainstay of therapy, began to surface a decade ago from multiple 
sites in central Africa. A sentinel surveillance network, HATSENTINEL, 
was created in 2002 to monitor temporal and geographical trends in the 
efficacy of chemotherapy.  We analyzed longitudinal surveillance data 
collected from 2002 to 2008 in facilities treating Trypanosoma brucei 
gambiense infection.   Although melarsoprol remains effective in some sites, 
markedly elevated treatment failure rates are present in areas of Democratic 
Republic of the Congo (61%) and northern Angola (98%).  The cause of 
melarsoprol-refractory infection has not been identified.  Eflornithine, the 
alternative drug, remains effective.  Continued monitoring of treatment 
effectiveness for human African trypanosomiasis is needed.   
 
 
 
 
 
 
 37 
INTRODUCTION 
 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is 
caused by Trypanosoma brucei, a protozoan parasite that is transmitted by 
the tsetse fly (Glossina spp.)  It is a neglected disease that continues to pose a 
health threat to rural Africans.  A decade ago, central Africa faced a major 
resurgence of the West African form of HAT, caused by T. b. gambiense 
(Burri and Brun 2003).  At the same time, the East African subspecies, T. b. 
rhodesiense was spreading to areas not previously endemic(Fevre, Picozzi et 
al. 2005).  Improved HAT control in recent years has reduced the incidence 
by ~70%, however, the 12,000-15,000 cases reported annually to the World 
Health Organization are thought to underestimate the true incidence of the 
infection(Simarro, Jannin et al. 2008). 
Effective drugs for HAT treatment are essential because the untreated 
infection is invariably fatal.  Furthermore, successful control of T. b. 
gambiense, which accounts for >90% of HAT cases, depends on 
chemotherapy, because humans constitute the principal infection reservoir.   
However, treatment of HAT currently relies on a very limited arsenal of 
drugs.  Of the 4 drugs registered for HAT, only 2 are useful for the majority 
of patients, who have central nervous system involvement (stage II HAT) at 
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the time of diagnosis.  Melarsoprol has been the mainstay of therapy for stage 
II HAT since it was introduced in 1949.  It is the only effective drug for 
treatment of stage II T. b. rhodesiense.  Eflornithine is an alternative to 
melarsoprol for stage II T. b. gambiense, either given as monotherapy or, 
recently, given in combination with nifurtimox(Priotto, Kasparian et al. 
2007), a drug indicated for Chagas disease. 
 
Melarsoprol efficacy (91-95%) showed little change in the first 50 years of 
use.  However, during the recent HAT resurgence, elevated rates of 
melarsoprol treatment failure were reported from T. b. gambiense-endemic 
areas of Uganda(Legros, Evans et al. 1999), Angola(Brun, Schumacher et al. 
2001), and Sudan(Moore, Richer et al. 1999).  The simultaneous appearance 
of treatment failure in geographically distinct and widely separated areas was 
of concern.  The scope of the problem was unknown, because treatment 
failure in most HAT-endemic areas was not closely monitored and 
methodology for calculating failure rates was not standardized.  A sentinel 
surveillance network (HATSENTINEL) was created in 2002 to gather data 
for monitoring geographical and temporal trends in treatment efficacy and to 
ascertain risk factors for treatment failure.  We present an analysis of 6 years 
of longitudinal HATSENTINEL data for areas endemic for T. b. gambiense.   
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METHODS 
Surveillance sites 
The HATSENTINEL network collects data from 9 HAT treatment facilities 
(Figure 1) in 5 countries.  The countries and specific sites were selected 
because of their high burden of disease and/or proximity to areas where 
treatment failure had been reported.  Seven sites are located in Democratic 
Republic of the Congo (DRC), Angola, or Sudan, where T. b. gambiense is 
endemic:  Mbuji Mayi (DRC 1), Katanda (DRC 2), Kionzo (DRC 3), 
Kimpese (DRC 4), Caxito (Angola 1), Mbanza Congo (Angola 2) and Kiri 
(Sudan 1).  Two sites are located in areas endemic for T. b. rhodesiense 
(Serere, Uganda and Kailua, Tanzania).  The facilities included health centers 
and hospitals operated by ministries of health, nongovernmental 
organizations, and a Catholic mission.  The level of care provided, compared 
to Western standards, would be considered basic.  Participating facilities 
varied in size (number of beds 9-100) and patient volume (35-650 HAT 
inpatients per year).  Data collection began in 2002 at 4 sites.  Five additional 
sites were added during 2003-2004.  
Surveillance data 
Two types of data are reported through the HATSENTINEL network.  To 
address the lack of standard diagnostic and treatment protocols used for HAT 
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in African facilities, data about the specific diagnostic methods and treatment 
regimens in use at the sentinel facilities are collected on a standardized form.  
A second report form is used to collect individual, anonymous patient data.  
These data include demographic information (age, sex, village of residence), 
HAT diagnostic information, treatment history, and current therapy.   This 
project conformed to the policies of the CDC Institutional Review Board. 
 
 
Inclusion criteria and case definitions 
HATSENTINEL collects case reports for all patients admitted to the 
participating facilities for treatment of infection with central nervous system 
involvement (stage II) and whose HAT diagnosis was made with a positive 
parasitological test (i.e., trypanosomes were observed in blood, lymph node 
aspirate, or cerebrospinal fluid (CSF)).  Patients were included in the analysis 
if they fulfilled the following case definition for stage II infection:  parasites 
observed in CSF, and/or CSF white blood cell count (WBC) >5/μl.   After 
completing a treatment course, according to the guidelines of the National 
HAT control programs, patients were instructed to return every six months 
over a two year period for follow-up examinations of their CSF. We used the 
following case definition for treatment failure:  any patient with parasite-
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confirmed HAT who presents with trypanosomes in CSF and/or a CSF 
WBC>50 cells/μl within a 2-year period following receipt of a complete 
treatment regimen appropriate for the initially diagnosed disease stage.  
Case reports for 5110 patients treated and followed from July, 2002 through 
September, 2008 were examined.  These reports were from the 6 sites 
endemic for T. b. gambiense in which >50 patients were treated during the 
surveillance period.  Data from a pilot study conducted at the site Angola 2 
were not included in the total 5510 but were used in the survival analysis. 
Reports for 206 patients were received from the 2 sites treating T. b. 
rhodesiense.  These patients are not included in this analysis, but our data 
show no evidence of elevated treatment failure rates in T. b. rhodesiense- 
endemic areas. 
 
 
Statistical Analysis 
Data were entered into an EpiInfo database (version 6) and were analyzed 
using SAS (version 9.1).  Univariate and multivariate analyses along with 
logistic regressions and Kaplan-Meier analysis for the probability of failure-
free survival were performed.  Trends in treatment failure rates were 
examined by stratifying data by quarter of admission as well as using 
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methods of survival analysis including the „survivor function‟ s(t) 
representing proportions of patients successfully treated after any given day t 
since treatment.  Treatment failure at any given day t is presented by the 
inverse function 1 minus s(t). 
 
RESULTS 
Site characteristics 
The sites all use serologic testing with the card agglutination test for 
trypanosomes (CATT) to screen patients but methods for performing 
parasitological exams varied. Detection of peripheral trypanosomes was 
through microscopy of blood or lymph node aspirate at all centers; some 
centers also used blood concentration techniques.  One center used 
Quantitative Buffy Coat (QBC) routinely (Sudan 1), one used capillary tube 
centrifugation (CTC) routinely (Angola 2) and three used anion exchange 
columns (mAECT) occasionally (DRC 1, DRC 2, DRC 3). Three centers 
staged by examining for trypanosomes in the CSF after double centrifugation 
(Angola 1, DRC 1, Sudan 1) while the other centers lacked centrifuges. 
Patients were treated for malaria if they are infected and most are 
presumptively treated for intestinal helminthes prior to receiving treatment 
for HAT. When surveillance began, melarsoprol monotherapy was the 
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treatment of choice for stage II HAT in 4 centers, although 3 centers 
subsequently changed to eflornithine monotherapy.  Two centers (Angola 1, 
Sudan 1) used eflornithine as their primary treatment throughout the 
surveillance period.  
 
 
Patient Characteristics 
A total of 5110 patients met the criteria for stage II HAT during the 
surveillance period.  While all ages were affected, most patients were adults 
with a median age of 31 and an inter-quartile range from 23-40. Male 
patients were the majority 3052 (60%), although the gender distribution 
varied with treatment center (Table 1).  A marked male predominance (67%) 
was found at DRC 1, where the facility catchment area included a large 
number of alluvial diamond miners.   
Overall, the proportion of patients receiving retreatment was high (36%).  
Most of these patients were admitted at the largest facilities (DRC 1 and 
DRC 2) where melarsoprol was first line therapy.   
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Treatment Failure 
More than 98% of the treatment failure detected by the HATSENTINEL 
network was after the use of melarsoprol (Figure 2).  Although the drug 
remained effective at 1 site (DRC 3), failure rates at the other 3 facilities 
using it were elevated (Table 2), compared to the rates observed historically 
(5-8%), regardless of whether we used for analysis the standard treatment 
failure case definition or a stricter case definition requiring trypanosomes to 
be found in CSF (Table 2). 
The mean interval between initial therapy and readmission for retreatment 
was 389 days.  However, this interval was considerably shorter at one site 
(Angola 2).  This site was atypical in both the rapidity of relapse and the high 
proportion of patients failing treatment.  In all sites, a small proportion of 
patients were diagnosed with treatment failure more than 720 days after 
initial therapy.   These were classified as new infections. 
Although facilities with elevated treatment failure rates ultimately adopted 
alternative first line therapy for stage II infections, we were able to monitor 
melarsoprol failure rates in 2 sites (DRC 1 and DRC 2) for 22 consecutive 
quarters.  We detected no rising or declining trends in treatment failure rates.   
Eflornithine was used to treat 2026 patients in 5 facilities (Sudan 1, DRC 1, 
DRC 2, Angola 1, Angola 2).  Failure rates for eflornithine were less than 
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5%, consistent with the reported efficacy of the drug (Pepin, Khonde et al. 
2000; Balasegaram, Young et al. 2009). 
 
 
Patient Characteristics Associated with treatment failure.  
Patient age, sex, and CSF WBC, trypanosomes in the CSF, and HAT relapse 
at the time of admission were examined as potential risk factors for treatment 
failure.  Having a CSF WBC > 100 was associated with treatment failure for 
melarsoprol with a relative risk of 1.82 (1.29-2.51 95% CI).   No significant 
association was found for other variables. 
 
DISCUSSION 
Elevated rates of melarsoprol failure were first noted a decade ago and were 
reported from HAT treatment programs at sites within Uganda(Legros, 
Fournier et al. 1999), Sudan(Moore, Richer et al. 1999), Angola(Stanghellini 
and Josenando 2001), and, more recently, from northern DRC(Robays, 
Nyamowala et al. 2008).  However, interpretation of these data and 
comparison of sites has been complicated by the use of different case 
definitions, variable completeness of follow-up, and the use of different 
denominators in calculating failure rates.  Our standardized data collection 
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and the use of Kaplan-Meier survival analysis confirm that melarsoprol-
refractory T. b. gambiense infection is present in several foci in central 
Africa.   
The melarsoprol failure rates documented by HATSENTINEL in northern 
Angola (98%) and in East Kasai Province of DRC (61%) are substantially 
higher than previously reported. Because parasites cannot always be 
demonstrated in the CSF of relapsing patients, the diagnosis of treatment 
failure often is based on clinical criteria and CSF WBC count.  However, 
melarsoprol failure rates unquestionably are elevated at these sites.  When a 
strict case definition requiring observation of CSF trypanosomes is used for 
analysis, the probability of failure within the 2 year follow-up period is 23-36 
%, which is significantly higher than the 5-8% rates seen in previous 
decades.  Melarsoprol failure at our sentinel sites was associated with 
elevated pre-treatment CSF levels of WBC, as observed by others (Legros, 
Evans et al. 1999; Schmid, Nkunku et al. 2004; Pepin and Mpia 2005; Lejon, 
Roger et al. 2008), but it was not associated with age, sex, or relapse status at 
the time of hospital admission. 
The elevated melarsoprol failure rates were independent of the specific 
treatment regimen administered, at least in the DRC sites, where both the 
traditional lengthy empirical schedule and the 10-day protocol(Schmid, 
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Nkunku et al. 2004) were used.   No significant increasing or decreasing 
trends in melarsoprol failure rates were observed during nearly 2 years of 
longitudinal data collection in East Kasai Province.  We also found no 
evidence of geographic spread of melarsoprol-refractory infection.   The drug 
remained effective at site DRC 3 during 6 years of surveillance, despite its 
proximity to the Angola 2 site, which had high rates of melarsoprol failure 
when surveillance began in 2002.  A similar observation was made at site 
Sudan 1.  Melarsoprol, which was used until 2003, remained 
effective(Balasegaram, Young et al. 2009) even though treatment failure had 
been reported from sites in the same province and nearby in Uganda for 
several years. 
The HATSENTINEL data have limitations.  Definitive methods for HAT 
cure assessment are lacking, and patients are regarded as cured after a 2-year 
disease-free interval after treatment.  This arbitrary cut-off may cause 
misclassification of patients.  Relapse patients who are readmitted for 
treatment after intervals longer than 2 years are classified as re-infected, 
resulting in lowered treatment failure rates.  Conversely, cured patients who 
are re-infected during the 2 year follow-up period may be misclassified as 
relapses.  However, because the HAT annual incidence is <1% at these sites, 
misclassification of re-infected patients is unlikely to alter treatment failure 
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rates significantly.  Another limitation arises from the level of patient 
compliance with follow-up, which varies with facility.  HATSENTINEL 
generally underestimates failure rates, because the network does not record 
patients who die from undiagnosed relapse away from the treatment center.  
However, one facility, DRC 1, occasionally provides retreatment to patients 
who were initially treated elsewhere, resulting in an apparent failure rate that 
may be somewhat higher than the true rate at that site.   
 
The underlying cause of melarsoprol-refractory infection has yet to be 
identified.  The likelihood that relapsing patients received sub-therapeutic 
doses of drug is low, because melarsoprol is given only as inpatient therapy 
by specialized health facilities experienced in HAT management.  
Incremental dosing, which has been associated with increased treatment 
failure(Pepin and Mpia 2005) was not used in the HATSENTINEL sites.  
Host-related factors, e.g. altered pharmacokinetics or immune status, may be 
playing a role.  However, to date, no pharmacokinetic differences between 
new and relapse patients have been observed (Burri and Keiser 2001).   The 
HIV status of patients at our sentinel sites is unknown, because testing is not 
routinely performed.  Although it is possible that reduced melarsoprol 
efficacy in HIV-infected patients is contributing to the high treatment failure 
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rates, it is probably not the sole cause.  In a Sudanese HAT focus where 
melarsoprol-refractory infection was present and patient HIV status was 
determined, failure rates were elevated for HIV-negative as well as for HIV-
positive patients (Moore, author‟s unpublished data).  HAT is not an 
opportunistic infection in HIV-infected persons (Noireau, Brun-Vezinet et al. 
1987; Meda, Doua et al. 1995), and the low HIV prevalence in rural areas 
endemic for T. b. gambiense cannot account for the high treatment failure 
rates observed.   
 
The role of resistant trypanosomes in human treatment failures is unclear.  
The existence of resistance to veterinary drugs is well established in 
trypanosome species pathogenic to animals.  Drug pressure on T. b. 
gambiense may have existed during the 1990‟s, because nearly half of the 
melarsoprol administered in the past 6 decades was given during the recent 
HAT resurgence. Melarsoprol resistance has been induced in laboratory 
strains of T. brucei and has been linked to the loss of an aminopurine 
transporter that mediates drug uptake(Carter and Fairlamb 1993).  The 
transporter is encoded by the TbAT1 gene(Maser, Sutterlin et al. 1999; 
Matovu, Stewart et al. 2003), but, although there are TbAT1 alleles 
circulating in the field that might be involved in resistance(Matovu, Geiser et 
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al. 2001), an association of these alleles with melarsoprol relapse has not 
been established.   Drug susceptibility testing of isolates from patients 
infected with T. b. gambiense has been limited by the difficulty of parasite 
isolation and propagation.  However, specimens from newly diagnosed HAT 
patients in sites of melarsoprol refractoriness in Uganda(Matovu, Enyaru et 
al. 2001) and Sudan(Maina, Maina et al. 2007) are susceptible to melarsoprol 
when tested either in vitro or in immunosuppressed mice.  We have studied a 
small number of isolates from relapsing patients at HATSENTINEL site 
DRC 1 and these are sensitive to melarsoprol when tested in vivo (B Dahl, 
author‟s unpublished results).  These findings suggest either that 
melarsoprol-sensitive parasites have a selective advantage during the process 
of cryopreservation and multiple sub-passages in rodents prior to 
susceptibility testing or that factors other than resistant trypanosomes are 
responsible for treatment failure.   
 
The magnitude of melarsoprol treatment failure was not recognized by the 
country HAT programs or participating facilities until formal surveillance 
was implemented with HATSENTINEL.  Continuing surveillance for 
efficacy and safety of HAT drugs is advisable for multiple reasons.  Although 
melarsoprol efficacy remains high at the HATSENTINEL sites where T. b. 
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rhodesiense is endemic, melarsoprol-resistant parasites have been found in a 
limited number of patients(Kibona, Matemba et al. 2006).  There is no 
alternative treatment for stage II infection with this subspecies.  The use of 
eflornithine monotherapy as first line treatment for stage II T. b. gambiense 
has expanded considerably.  While our data show that eflornithine remains 
fully effective at present, there is some concern about its widespread use as 
monotherapy.  Eflornithine may be particularly vulnerable to the 
development of resistance because of its short half-life, cytostatic mode of 
action, and uncertain efficacy in patients co-infected with HIV(Pepin, Ethier 
et al. 1992).  Furthermore, it requires 4 daily intravenous infusions and a 
level of nursing care that is difficult to achieve in some facilities, so 
monitoring for adverse events as well as for efficacy is needed.  Eflornithine 
is currently the only alternative to melarsoprol for treatment of T. b. 
gambiense infection.  However new combination regimens are being 
explored (Bisser, N'Siesi et al. 2007; Checchi, Piola et al. 2007).  Nifurtimox 
given in combination with a reduced dose of eflornithine appears very 
promising (Priotto, Kasparian et al. 2007), based on the results of recently 
completed clinical trials, and it may be in field use in the near future.  Two 
product development groups, the Drugs for Neglected Disease Initiative and 
the Consortium for Parasitic Drug Development, have new HAT drugs in 
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their pipelines.   Because of the limited number of treatment centers and the 
challenges of conducting trials in remote facilities, HAT clinical trials 
generally do not enroll large numbers of patients.  Continued surveillance 
and monitoring of newly introduced therapy will be needed.   
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Table 1.  Demographic and clinical characteristics of HATSENTINEL patients with stage II T. b. gambiense infection, 
2002-2008 (n=5110). 
 
 DRC 1 DRC 2 DRC 3 Angola 1 Angola 2 Sudan 1 
Total no. of patients 2754 1421 177 73 141 542 
Mean age in years 
(range) 
Age group 
0-5 (%) 
6-15 (%) 
16-55 (%) 
56- (%) 
34.4  
(3-80) 
 
8 (0.3) 
55 (2) 
2561 (93) 
130 (4.7) 
30.2 
(1-88) 
 
70 (4.9) 
137 (9.6) 
1125 (79) 
89 (6.3) 
29.3 
(1-82) 
 
11 (6.2) 
28 (16) 
129 (72.9) 
9 (5) 
32.5 
(1-85) 
 
1 (1.4) 
9 (12.3) 
58 (79.5) 
5 (6.8) 
29.2 
(1-73) 
 
3 (2.1) 
25 (17.7) 
105 (74.5) 
8 (5.7) 
29.2 
(1-65) 
 
24 (4.5) 
145 (26.8) 
352 (64.9) 
21 (3.9) 
Male patients (%) 1837 (67) 689 (49) 87 (49) 41 (57) 87  (62) 311 (58) 
Admission for new HAT 
diagnosis 
1512 867 167 70 126 521 
   -Mean CSF WBC (cell/μl) 331 138 272 247 237 231 
   -Trypanosomes in CSF (%) 1080 (71) 460 (53) 101 (61) 70 (100) 76(60) 230(44) 
Admission for HAT retreatment 1242 554 10 3 15 21 
   -Mean CSF WBC (cell/μl) 238 137 213 127 149 337 
   -Trypanosomes in CSF (%) 642 (52) 200 (36) 14 (82) 2(67) 11 (73) 14 (67) 
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Table 2.  Treatment failure within 730 days in patients with stage II T. b. gambiense infection, 2002-2008 (n=5110).   
 
  Melarsoprol Eflornithine 
Site Total 
treated 
 
Total 
treated  
Failed 
treatment, 
standard case 
definition  
(%) 
Failed treatment, 
trypanosomes in 
CSF (%) 
Total 
treated  
Failed 
treatment, 
standard case 
definition  
(%) 
Failed treatment, 
trypanosomes in 
CSF  
(%) 
DRC 1 2754 2022 1113 (55) 642  (32) 732 17 (2.32) 9 (1.23) 
DRC 2 1421 866 541 (62) 200 (23) 555 13 (2.34) 9 (1.62) 
DRC 3 177 177 10 (6) 7  (4) 0 0 0 
Angola 
1 
73  5 0 0 68 3 (4.) 2 (3) 
Angola 
2 
143  14 14 (100) 5 (36) 129 4 (3) 1 (1) 
Sudan 
1 
542 0 0 0 542 21 (4) 14 (3) 
Total 5110 3084 1790(58) 854 (28) 2026 55 (3) 35 (2) 
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Figure 1.  Surveillance for Human African Trypanosomiasis 
Treatment Failure.  Sentinel Sites, 2002-2008.  (1=DRC 1; 2=DRC 2; 
3=DRC 3; 4=DRC 4; 5=Angola 2; 6=Angola 1; 7=Sudan 1; 8=Uganda; 
9=Tanzania) 
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Figure 2.  Proportion of patients failing treatment (by center) for stage II T. b. gambiense infection during the two year 
follow-up period. Shown as inverse Kaplan-Meir curves (1-s(t)). *(includes data from pilot study at Angola 2) 
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effectiveness of eflornithine monotherapy for Trypanosoma brucei 
gambiense at four sentinel sites 
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Introduction: 
Human African Trypanosomiasis (HAT), also known as sleeping sickness, is 
still a public health problem in several countries in sub-Saharan Africa, with 
close to 12,000 new infections reported in 2006(Simarro, Jannin et al. 2008).  
The West African form of the disease, which is caused by Trypanosoma 
brucei gambiense, accounts for more than 95% of cases.  Although the 
incidence is lower than other infectious diseases, such as malaria or 
tuberculosis, the impact of HAT on the health sector and on endemic 
communities is considerable.  Untreated HAT is fatal, and a substantial 
proportion of infected persons remain undiagnosed and untreated(Odiit, 
Coleman et al. 2005).   Of those who ultimately receive treatment, the 
majority have central nervous system involvement (stage II disease) at the 
time of diagnosis.  These patients require inpatient therapy, which is often 
intensive and lengthy.  
Only a limited number of drugs are available for treatment of HAT (Croft, 
Barrett et al. 2005; Moore 2005).  Reduced effectiveness of melarsoprol, a 
mainstay of HAT chemotherapy for more than 50 years, is being reported 
from an increasing number of sites endemic for T. b. gambiense(Legros, 
Evans et al. 1999; Brun, Schumacher et al. 2001; Robays, Nyamowala et al. 
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2008).  Eflornithine is the only alternative to melarsoprol that is registered 
currently for T. b. gambiense infection, and its use has expanded 
considerably in recent years.  
 
A network of sentinel health facilities (HATSENTINEL) was established in 
2002 to collect standardized surveillance data about geographic and temporal 
trends in HAT treatment efficacy.    Initial data from HATSENTINEL 
showed a consistently high probability of melarsoprol treatment failure in 
East Kasai Province in the Democratic Republic of The Congo (DRC) (B 
Dahl, author‟s unpublished data).  The high level of melarsoprol-refractory 
infections led the DRC sleeping sickness program to change first line therapy 
for stage II infection to eflornithine in 2006.  We present HATSENTINEL 
data collected from 2003 to 2008 on eflornithine effectiveness from 4 
sentinel hospitals, including 2 sites where eflornithine was introduced as first 
line therapy in 2003 and the 2 sites in DRC where it has been used since 
2006.   We also examine the impact of the change in first line therapy on the 
health care facilities and staff.  
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Methods 
 
Surveillance sites 
The HATSENTINEL network collects data from 9 HAT treatment facilities 
in 5 countries.  Four of these sites used eflornithine for stage II T. b. 
gambiense infection:  Mbanza Congo, Angola (since 2003), Kiri, Sudan 
(since 2003), Mbuji Mayi, DRC (since 2006), and Katanda, DRC (since 
2006).  The sites in Angola and DRC are government-run hospitals.  The site 
in Sudan was run by Médecins Sans Frontières, Switzerland during the 
surveillance period. The facilities varied in size (9-100 beds) and patient 
volume (35-650).  The hospital at Mbuji Mayi differed somewhat from the 
others in that it admitted patients from the local community, but it functioned 
also as a reference center and handled admissions of patients who had 
unsuccessfully been treated for HAT elsewhere. 
 
Data Collection 
Facility data.  To address the lack of standard diagnostic and treatment 
protocols for HAT in African facilities, data about the specific diagnostic 
methods and treatment regimens in use at the sentinel facilities were reported 
on a standardized form.  In the 2 facilities in DRC (Mbuji Mayi and Katanda) 
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where first line therapy was changed during the surveillance period, we 
collected information about the impact of the change through semi-structured 
interviews with hospital staff and patients.   
The staff were asked about the impact the change of therapy had on their 
workload and stress, changes in the frequency and types of adverse reactions, 
issues related to the addition of an overnight shift, and which drug they 
preferred administering.  
In similar interviews patients were asked about reasons for selecting the 
treatment facility, how they were responding to treatment, and if it was a 
repeat treatment, how it compared with the previous. 
Patient data. A standardized form was used to report individual, anonymous 
patient data that included demographic information (age, sex, village of 
residence), HAT diagnostic information, treatment history, and current 
therapy.   This project conformed to the policies of the CDC Institutional 
Review Board. 
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Inclusion criteria and case definitions 
 
HATSENTINEL collects case reports for all patients admitted to the 
participating facilities for treatment of stage II infection and whose HAT 
diagnosis was made with a positive parasitological test (i.e., trypanosomes 
were observed in blood, lymph node aspirate, or cerebrospinal fluid (CSF)).  
We used the following case definition for stage II infection:  parasites 
observed in CSF, and/or CSF white blood cell count (WBC) >5/ul.   After 
completing therapy, patients are followed with examinations of CSF every 6 
months for 2 years.  We defined treatment failure as:  any patient with 
parasite-confirmed HAT who presents with trypanosomes in CSF and/or a 
CSF WBC>50 cells/µl within a 2-year period following receipt of a complete 
treatment regimen appropriate for the initially diagnosed disease stage.   Our 
analysis includes case reports for all patients meeting the criteria for stage II 
infection and who were treated with eflornithine at the participating facilities 
between January 2003 and September, 2008. 
 
Statistical Analysis 
Data were entered into an EpiInfo database (version 6) and were analyzed 
using SAS (version 9.1).  Univariate and multivariate analyses along with 
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logistic regressions and Kaplan-Meier analysis for the probability of failure-
free survival were performed.  Trends in treatment failure rates were 
examined by stratifying data by semester of admission as well as using 
methods of survival analysis including the „survivor function‟ s(t) 
representing proportions of patients successfully treated after any given day t 
since treatment.  Treatment failure at any given day t is presented by the 
inverse function 1 minus s(t). 
 
RESULTS 
Eflornithine effectiveness  
The four centers that used eflornithine varied in patient volume (Table 1), but 
patient demographic characteristics were similar, with the exception of the 
facility in Mbuji Mayi, which had a higher proportion of male patients.   For 
patients who failed eflornithine, the mean interval between initial therapy and 
admission for retreatment was 408 days (30-723).  The cumulative incidence 
of treatment failure within 730 days ranged from 2.3 % to 3.9% (Table 1). 
This incidence did not differ significantly between treatment-naïve patients 
and patients who had failed previous therapy with melarsoprol.  No 
increasing or decreasing trends in the probability of failure-free survival were 
noted when data were analyzed by semester.   
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Patient age, sex, WBC count in CSF, and the presence of CSF trypanosomes 
were examined as potential risk factors for failing eflornithine therapy.   We 
found no statistically significant association of these variables with 
eflornithine treatment failure.  However, at all four centers, trypanosomes 
were found in the CSF at initial diagnosis more frequently in patients who 
failed treatment with eflornithine (16 of 24) than those who had failed with 
melarsoprol (204 of 452) with an odds ratio of 2.43 (95% CI, 1.02-5,8; p-
value=0.039).   
 
Eflornithine as first line therapy: impact on health facilities 
The two facilities in DRC that changed from melarsoprol to eflornithine for 
initial stage II HAT therapy experienced a substantial reduction in the 
proportion of patients seeking retreatment (Figure 1).  This resulted in a 
marked decrease of HAT admissions.  At the Katanda facility, the 
introduction of eflornithine reduced the number of admissions from an 
annual mean of 268 in 2003-2006 to 220 in the period 12-24 months after 
making the change.  A similar decrease in patient volume was seen at the 
Mbuji Mayi hospital, from 499 patients annually to 301.   
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Interviews with hospital staff found near unanimous support for the switch to 
eflornithine (11 of 12 staff interviewed). Initial reluctance due to the 
increased frequency of dosing changed to an overwhelming (92%) 
endorsement because of the reduction of adverse events, near elimination of 
deaths, and more manageable workload.  The sole issue of contention was the 
near universal dislike of working the overnight shift.  
Discussion 
Our longitudinal surveillance data for HAT treatment failure at these 4 
sentinel sites show that eflornithine remains an effective therapy for stage II 
disease, even in areas where melarsoprol-refractory infection is present.  The 
cumulative incidence of 2.3%-3.9% eflornithine failure at 2 years post-
therapy is actually even lower than previously reported for this drug (Milord, 
Pepin et al. 1992; Balasegaram, Young et al. 2009).  No difference in failure 
rate is found between new patients and those who receive eflornithine for 
relapse after melarsoprol treatment.    
Previous studies have identified high initial CSF WBC counts (Chappuis, 
Udayraj et al. 2005; Checchi and Barrett 2008) and, in some reports (Checchi 
and Barrett 2008), the presence of CSF trypanosomes as risk factors for 
eventual treatment failure.   These were not associated with failure in our 
analysis, probably because of the limited number of patients who relapsed 
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and the lack of statistical power.  Additional studies are needed to interpret 
our finding that CSF trypanosomes are present more frequently in patients 
who ultimately relapse after eflornithine therapy than those relapsing after 
melarsoprol.    
 
These data may underestimate eflornithine failures, because our surveillance 
fails to record patients who may be treated at other facilities or who die 
during the 2 year follow-up period.  However, assuming that patients with 
adequate follow-up are similar to those who are lost, the adjusted failure rates 
would still be consistent with the known efficacy of eflornithine (Milord, 
Pepin et al. 1992; Balasegaram, Young et al. 2009).  The facility at Mbuji 
Mayi serves as a referral center and admits patients who have failed therapy 
elsewhere, so failure rates at that site may be overestimated.  Cured patients 
who are reinfected during the follow-up period are classified as relapses, but 
these are not likely to alter failure rates significantly because the HAT 
incidence in the catchment areas of the sentinel sites is <1%.   
 
HATSENTINEL surveillance data found markedly elevated melarsoprol 
treatment failure rates (55%--62%) at the Mbuji Mayi and Katanda sites in 
2003-2005 (B Dahl, authors unpublished data).  The change to eflornithine as 
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initial therapy yielded multiple benefits.   Not only did patients experience 
sharply lower rates of treatment failure but also a lower case fatality rate.   
The mortality rate for patients treated with eflornithine was 2% at these 
facilities compared with 7% for patients who received melarsoprol.  HAT 
patients were well aware of the superior outcomes with eflornithine and 
preferred it to melarsoprol. 
 
The change in therapy also provided benefits to the health system.   HAT is 
prevalent in poor countries where health care spending is minimal and access 
to care limited. Health centers and hospitals are often understaffed and those 
who are present are overworked.  For example, the Katanda center functioned 
with only one nurse for several years.   In these settings, patients returning 
for treatment a second or third time can burden the staff and overwhelm the 
system.  Centers may be forced to have patients share a bed or delay 
treatment.  After introduction of eflornithine as initial treatment at the DRC 
sites, patient volume became more manageable.  In 2005, the hospital in 
Mbuji Mayi admitted 612 stage II HAT patients for treatment; in the last year 
of our surveillance (September 2007-September 2008) that figure had been 
cut to 301. This reduction is primarily attributable to a decrease in the 
number of patients seeking retreatment. The Katanda site also had reductions 
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in patient volume from 390 in 2005 to 220 in 2007-2008.   Interviews with 
hospital staff showed an evolution of how eflornithine was perceived. While 
hospital staff in Mbuji Mayi were familiar with the medication before the 
switch and realized it was an excellent option for melarsoprol-refractory 
cases, the health care workers also noted that the 4 daily intravenous 
infusions needed for eflornithine administration were labor intensive and 
required close monitoring for catheter infections. This led to an initial 
reluctance to administer it to every stage II patient, especially because of the 
large patient volume. This view began to change as the staff became more 
familiar with administering the drug to more patients.  Providing care with 
eflornithine was viewed as less stressful, because melarsoprol-induced the 
encephalopathic reactions were avoided.  Although eflornithine is donated 
free of charge, its use of eflornithine generated additional costs to the 
sleeping sickness programs, because overnight staff must be present to 
administer it.  However, these costs were balanced by the lower overall 
patient volume. 
 
It has been recognized for some time that eflornithine is effective and safer 
than melarsoprol in treating stage II HAT(Chappuis, Udayraj et al. 2005; 
Checchi and Barrett 2008; Balasegaram, Young et al. 2009) but the 
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logistically difficult schedule of administration was viewed as a barrier to its 
widespread use.  Our data show that acceptability of eflornithine is high 
among hospital staff and patients.  We anticipate that its use will continue to 
increase.  Eflornithine is trypanostatic, rather than trypanocidal.  Because of 
the difficult schedule of administration, especially in understaffed facilities, 
doses may be missed.  This may lead to subtherapeutic drug levels, given 
eflornithine‟s short half-life.  The question of potential development of drug 
resistance has been raised.  Combination of a reduced dose of eflornithine 
with oral nifurtimox appears to be very promising(Priotto, Kasparian et al. 
2007) and is expected to be in field use in the near future.   This may offer 
some protection against the development of drug resistance, however, the 
dosing schedule has peaks and troughs in eflornithine levels.  Continued 
surveillance for treatment failure of eflornithine monotherapy and 
combination therapy will be needed.  
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Table 1.  Characteristics and Clinical Outcomes of Patients treated for stage II HAT with eflornithine, 2003-2008 (n= 1969) 
 
Site  
Total treated  
Mbuji Mayi 
732 
Katanda  
555 
Kiri  
553 
M’Banza Congo 
129 
Mean age (range) 34 (3-80) 30 (1-88) 29 (1-65) 29 (1-73) 
No. female (%)   244 (33) 286 (52) 228 (41) 56 (39) 
Mean CSF WBC (range) 291 (5-5520) 136 (6-2890) 223 (5-7311) 234 (5-1565) 
CSF trypanosomes (%) 454 (62) 222 (40) 249 (45) 79(61) 
Treatment history     
Treatment naïve (%) 482 (66) 387 (70) 520 (94) 110 (85) 
Treatment failure (%)* 15 (2.1) 12 (2.2) 21 (3.8) 4 (3.9) 
Deaths (%) 15 (2.1) 12 (2.2) 2 (0.4) 7 (5.4) 
Previously treated (%) 250 (34) 168 (30) 33 (5.9) 19 (14.7) 
Treatment failure (%)* 2 (0.27) 1 (0.18) 0 0 
Deaths (%) 0 0 0 0 
*Admitted for retreatment within 730 days of initial therapy 
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Figure1. Proportion of sleeping sickness patients readmitted for treatment at two sites in the East Kasai Province of the 
Democratic Republic of Congo, by year 
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Introduction 
Human African Trypanosomiasis (HAT) is a parasitic disease transmitted 
through the bite of the tsetse fly (Glossina ssp.) found in 36 countries in sub-
Saharan Africa (Fevre, Picozzi et al. 2006; Maudlin 2006). There are two 
subspecies or strains that infect man. T.b. rhodesiense is a zoonosis and 
control efforts focus on the vector. T.b. gambiense is the other subspecies, 
responsible for 90-95% of infections in humans.  The most important 
reservoir for T. b. gambiense is man (Leak 1999), and effective treatment is 
vital for control efforts, because identifying and treating those infected will 
reduce the prevalence of disease. There are only four drugs available for the 
treatment of HAT, pentamidine and suramin for stage I disease and 
eflornithine and melarsoprol for stage II(Croft, Barrett et al. 2005). 
Melarsoprol has been the primary drug used since 1949, with an efficacy of 
91-95%. In the late 1990‟s elevated melarsoprol failure levels for T.b. 
gambiense were observed in Angola, Uganda and Sudan (Legros, Evans et al. 
1999; Moore, Richer et al. 1999; Burri and Keiser 2001). This led to 
questions about resistant parasites(Maser, Luscher et al. 2003), but few 
isolates from patients have undergone drug susceptibility testing  because of 
the technical difficulties in isolation and cryopreservation (Likeufack, Brun 
et al. 2006).  
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Recently there have been new developments in cryopreservation that have the 
potential to improve the feasibility of collecting field samples (Maina, Kunz 
et al. 2006; Maina, Oberle et al. 2007). To date, testing has been performed 
for a limited number of specimens collected from HAT foci in which 30% to 
50% of patients relapse after treatment with melarsoprol.  These were 
melarsoprol sensitive when tested in vitro (Brun, Schumacher et al. 2001; 
Maina, Maina et al. 2007). 
Melarsoprol resistance has been induced in laboratory isolates and is linked 
to the loss of an aminopurine transporter, P2, that mediates the uptake of the 
drug and of its metabolite, melarsen oxide (Carter and Fairlamb 1993; 
Barrett, Zhang et al. 1995; Carter, Berger et al. 1995).  This laboratory 
resistance, along with the presence of melarsen oxide, has raised questions of 
whether the in vitro methods used previously are adequate for detecting 
melarsoprol resistance in field isolates.  
Three sites participating in the HATSENTINEL network documented levels 
of melarsoprol-refractory HAT infection that exceeded 50%.  To investigate 
the cause of treatment failure, the new cryopreservation method was used to 
isolate parasites from patients at one of these sites, the Dipumba Hospital in 
the town of Mbuji Mayi in the East Kasai province of the Democratic 
Republic of the Congo.  These specimens were collected through 
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HATSENTINEL and another study (Pyana, unpublished data).  T. b. 
gambiense from 15 patients at this site were melarsoprol-sensitive when 
tested in vitro (Pyana, unpublished results).  This report describes parasite 
isolation and melarsoprol susceptibility testing in vivo of specimens from 
Dipumba Hospital.    
 
Methods 
Specimen source and collection 
Procedures developed by Reto Brun‟s lab (Brun, Schumacher et al. 2001; 
Maina, Kunz et al. 2006) were followed. Technicians collected 2ml of blood 
from patients at Dipumba Hospital who had been diagnosed with stage II 
disease; for a patient to be included, trypanosomes had to be identified 
through microscopy. Blood specimens were centrifuged for 10 minutes at 
1000g (11k rpm with model of centrifuge we used). The pellets were 
resuspended in 1ml of Triladyl® (1:1).  
Cryopreservation and propagation 
The samples were divided into 4 aliquots (0.5ml), labeled, and placed in a 
liquid nitrogen dry shipper for storage. The patient‟s admission data was 
recorded in a notebook with identifying information such as name or hospital 
ID number removed to assure anonymity (table 1).  
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HATSENTINEL specimens were collected during 2 time periods.  Twenty 
specimens were obtained in the first two weeks of September 2004 and 11 
specimens were obtained in August 2008.  These were stored in a dry shipper 
and transported to the Swiss Tropical Institute in Basel. The cryopreserved 
parasites from the infected HAT patients were administered to susceptible 
rodents (SCID and BALB/c mice) for propagation. We examined an 
additional 4 specimens that were obtained from patients at Dipumba Hospital 
who had failed melarsoprol that were previously collected (Pyana, 
unpublished) in 2006 and stored at the Swiss Tropical Institute.  
 
In vitro drug susceptibility 
Four specimens, which were collected in 2006, had been previously been 
tested for drug susceptibility in vitro using an incorporation of 
3
H-
hypoxanthine in culture at serial drug dilutions for measuring the IC50 (Pyana, 
unpublished).  The trypanosomes were harvested from the infected rodents 
through a cardiac puncture and separated according to the methods used by 
Maina et al (Maina, Maina et al. 2007). 
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In vivo drug susceptiblity 
Balb/c mice were used for the testing. The techniques developed in Reto 
Brun‟s lab were followed (Maina, Maina et al. 2007). The mice were 
immunosuppressed with 300 mg/kg bwt cyclophosphamide (Endoxan®) 48 
hours prior to infection and on days 14 and 28 post infection. Four isolates 
were selected from samples collected during a previous study at the same 
location [Pyana, unpublished data]. These specimens were used to infect 11 
mice intraperitoneally. The mice were then separated into three groups; 3 
mice served as controls, 4 received a melarsoprol dose for 4 days at 1 mg/kg, 
and 4 received a   melarsoprol dose for 4 days at 4 mg/kg. Parasitemia was 
determined by examining tail blood on day 3, 7, 10, 14, 17, 21, 24, 28 and 
31.  
 
Results 
The protocol at STI for monitoring for parasitemia in the rodents calls for 
examining of blood every other day for 60 days. However, we were unable to 
propagate parasite from any of the 20 specimens collected in 2004.  No 
rodents became parasitemic. It is unclear what caused the failure but theories 
include problems with the freshness of the egg yolks procured on-site, cold-
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chain issues related to the Triladyl®, and concerns about the rapidity of 
freezing.  
The 2008 samples were inoculated in SCID mice and parasitemia was 
followed, however the results were the same as with the stabilates from 2004 
with no samples being viable for drug susceptibility testing. This lack of 
success compares poorly to the results previously seen(Maina, Oberle et al. 
2007) where approximately 45% of stabilates propagated viable 
trypanosomes.  
Melarsoprol drug susceptibility in vivo was examined for 4 stabilates 
collected in 2005.  These were all sensitive to the drug (table 2).  Six out of 
seven mice were free of parasites after 7 days and all 7 were cured by day 31. 
 
Discussion 
The samples that were tested in vivo and were susceptible to melarsoprol are 
consistent with results seen elsewhere(Brun, Schumacher et al. 2001; 
Matovu, Enyaru et al. 2001; Likeufack, Brun et al. 2006). This supports the 
argument that there is not resistance to melarsoprol in T.b. gambiense and 
that other factors must be responsible for refractory cases.  The samples came 
from patients who had previously failed melarsoprol treatment; the isolates 
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had additionally been tested in vitro where they were also sensitive to 
melarsoprol [Pyana, unpublished data]. 
Resistance has been observed with T.b. rhodesiense(Kagira and Maina 2007) 
and T.b. brucei(Fairlamb, Carter et al. 1992) so the idea of demonstrating 
resistance with T.b. gambiense was an interesting prospect. The lack of 
success propagating trypanosomes from an area with elevated rates of 
treatment failure was disappointing.  The cryopreservation methods have 
worked in rural South Sudan(Maina, Oberle et al. 2007), in an environment 
that is arguably more technically challenging than the site in DRC. One of 
the first questions concerned the quality and age of the Triladyl® and if it had 
potentially been outside of the cold-chain long enough to render it unusable. 
However, the STI had identical stock remaining on-site in Basel and this was 
tested by cryopreserving an existing strain; the trypanosomes remained viable 
after freezing. Therefore, it is likely that our Triladyl® quality was adequate. 
A second hypothesis is that there was a problem with the freezing and that 
the sudden drop into the vapor phase of a nitrogen dry-shipper could have 
damaged the trypanosomes so that they were not viable upon arrival in Basel. 
It will be difficult to ascertain if this is true, however we followed the exact 
protocol that was used successfully in Sudan (Maina, Oberle et al. 2007). 
This raises the possibility that the strains of T.b. gambiense in central DRC 
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are different than those in Sudan and are less stable for cryopreservation 
though this is doubtful. 
 
We found that parasites from patients with melarsoprol-refractory infection 
are sensitive to melarsoprol when tested in vivo.  These results are consistent 
with previous in vitro testing of these and other stabilates collected in sites 
with high melarsoprol failure rates (Brun, Schumacher et al. 2001; Maina, 
Maina et al. 2007; Maina, Oberle et al. 2007)). 
It should be noted that the in vitro and in vivo drug sensitivity testing was 
conducted using parasites that had undergone multiple sub-passages in 
rodents.  It is not possible to perform direct testing with patient specimens, 
because the level of parasitemia in T. b. gambiense infection is low, the 
parasites do not grow well in vitro, and they have low virulence in rodents.  
Therefore, we cannot rule out the possibility that clonal selection is 
occurring, with a selective advantage for melarsoprol-sensitive parasites.  It 
will be difficult to address this issue until molecular markers for resistance 
are available or resistance testing can simplified (Stewart, Krishna et al. 
2005; Njiru, Mikosza et al. 2008).   Laboratory-induced melarsoprol 
resistance is associated with the P2 transporter (Carter and Fairlamb 1993; 
Barrett, Zhang et al. 1995; Carter, Berger et al. 1995). We did not try to 
 88 
determine if mutant alleles of the TbAT1 gene, which codes for the 
transporter (Maser et al. 1999; Matovu et al. 2001), were present in our 
specimens, however, an association of these alleles with clinical treatment 
failure has not been found when examined previously (Maina, Maina et al. 
2007).   
 
It is possible that factors other than reduced melarsoprol susceptibility are 
responsible for the high rates of clinical treatment failure.  Host-related 
factors need further investigation.   Patient HIV status is not usually 
determined in the hospitals where sleeping sickness is treated, and therefore 
data about patient immune competence is very limited at present.  Parasite-
related factors other than drug sensitivity also should be examined.  This 
might involve studying strain differences in the affinity of the parasite for 
certain tissues or sites that may have minimal exposure to melarsoprol.. The 
WHO is in the process of creating a specimen bank that will include samples 
collected in the East Kasai foci. It is hoped that those samples will be 
available for study and that a definitive answer to the cause of melarsoprol 
treatment failure will be found.  
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Table 1 Characteristics of patients who provided specimens for T.b. gambiense drug 
susceptibility testing, Mbuji Mayi, DRC 
year sampled sample # sex age 
CSF 
WBC at 
diagnosis 
2004 1 f 6 154 
2004 2 m 43 208 
2004 3 f 5 566 
2004 4 m 35 146 
2004 5 m 36 259 
2004 6 f 17 602 
2004 7 m 32 570 
2004 8 m 41 162 
2004 9 m 18 253 
2004 10 m 27 517 
2004 11 m 44 1370 
2004 12 m 40 301 
2004 13 m 31 80 
2004 14 m 38 953 
2004 15 f 40 761 
2004 16 m 31 79 
2004 17 m 25 1416 
2004 18 m 35 218 
2004 19 m 31 1559 
2004 20 m 30 76 
     
2008 1 m 48 259 
2008 2 m 36 386 
2008 3 m 46 25 
2008 4 f 19 130 
2008 5 m unknown 23 
2008 6 m unknown 127 
2008 7 f 31 158 
2008 8 m 42 1050 
2008 9 f 28 199 
2008 10 m 46 26 
2008 11 m 31 24 
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Table 2 In vivo melarsoprol drug sensitivities of T.b. gambiense isolates from Mbuji Mayi, DRC 
              
compound 
dose 
days 
x 
mg/kg 
route                     
                    
      mouse 
day 
3 
day 
7 
day 
10 
day 
14 
day 
17 
day 
21 
day 
24 
day 
28 
day 
31 
Control - -                     
      R ((+)) ++ ++ ++ (+) (+) + 0 0 
    St 0 ++ ++ ++ (+) (+) ((+)) 0 ((+)) 
      K St 0 ((+)) ((+)) ++ ((+)) ((+)) ((+)) 0 0 
compound 1 4x 1 i.p. K 0 0 0 0 0 0 0 0 0 
  Melarsoprol   R ((+)) 0 0 0 0 0 0 0 0 
    St ((+)) 0 0 0 0 0 ((+)) 0 0 
      K St ((+)) 0 0 0 0 0 0 0 0 
compound 2 4x 4 i.ip. K ((+)) 0 0 0 0 0 0 0 0 
  Melarsoprol   R ((+)) 0 0 0 0 0 0 0 0 
    St 0 0 0 0 0 0 0 0 0 
      K St* 0                 
                     
   0 No trypanosomes      
   ((+)) 1 Trypanosome per 20 fields    
   (+) 1 Trypanosome per field     
   + 2 - 5 Trypanosomes per field    
   ++ 6 - 20 Trypanosomes per field    
   +++ > 20 Trypanosomes per field    
             
   
*K St died at 
day 7        
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Introduction  
Human African Trypanosomiasis is a parasitic disease spread by the bite of 
the tsetse fly (Glossina ssp.) and was a major public health problem for the 
first half of the 20
th
 century(Burri and Brun 2003). Intensive control 
programs reduced the disease to fewer than five thousand cases annually by 
the 1960‟s, the majority of which were T.b. rhodesiense.  However priorities 
shifted and cases began to increase; by the early 1990s the prevalence was 
estimated to be between 300,000 and 500,000 cases (Cattand, Jannin et al. 
2001; Fevre, Picozzi et al. 2006). The reemergence was predominantly a 
geographical spread of central African cases of T.b. gambiense. The increase 
in cases was most evident in Angola, DR Congo and Sudan, countries that 
have all been suffering from conflict and war (Moore, Richer et al. 1999; Van 
Nieuwenhove, Betu-Ku-Mesu et al. 2001; Abel, Kiala et al. 2004). A 
concerted effort to control the disease has led to a decrease from the peak 
numbers seen in the late 1990‟s.  Currently there are under 12,000 cases 
registered annually and prevalence is estimated to be between 50,000 and 
70,000(WHO 2006; Simarro, Jannin et al. 2008).  The majority of these cases 
are treated at remote facilities that offer only basic levels of care.  
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Treatment of HAT is necessary since the disease is 100% fatal left untreated 
and yet there are currently only four drugs licensed for treatment(Croft, 
Barrett et al. 2005). Pentamidine and Suramin are used to treat Stage I 
disease, the period before the parasite has crossed the blood-brain barrier. 
The other two drugs available, eflornithine and melarsoprol(Balasegaram, 
Young et al. 2009), are for Stage II disease where the parasites have entered 
the central nervous system; eflornithine, however, is only effective against 
T.b. gambiense.  Eflornithine‟s use for treatment has recently increased 
dramatically and is being advocated(Chappuis, Udayraj et al. 2005). 
Melarsoprol has been the primary drug for second stage disease for the past 
50 years. In certain foci, elevated levels of treatment failure began to be 
recognized from 1999-2001 in distinct foci (Legros, Evans et al. 1999; 
Legros, Fournier et al. 1999; Brun, Schumacher et al. 2001; Burri and Keiser 
2001) . Additional sentinel surveillance revealed high rates of melarsoprol 
failure in several more foci [HATSENTINEL]. Therapeutic alternatives such 
as nifurtimox-eflornithine combination therapy are being examined (Checchi, 
Piola et al. 2007; Priotto, Kasparian et al. 2007). These changes should be 
followed with appropriate care.  
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Challenges for implementing pharmacoepidemiology/pharmacovigilance 
for HAT 
Pharmacovigilance (PV) and pharmacoepidemiology (PE) has its basis in the 
monitoring of adverse events for drugs that have been approved and are 
being marketed(ISPE 2007). The World Health Organization has advocated 
for greater monitoring of medicinal products (WHO 2002) and this paper will 
be working with their definition of pharmacovigilance, “the science and 
activities relating to the detections, assessment, understanding and prevention 
of adverse effects or any other possible drug-related problems.” 
Pharmacovigilance falls under the broader topic of pharmacoepidemiology, a 
field that applies “epidemiologic methods to pharmacological issues”(ISPE 
2007).  
In the US, the Food and Drug Administration offers guidance and 
recommendations for how pharmacovigilance should be approached(US 
Health and Human Services 2005). Companies are required to monitor for 
drug safety as part of the post-licensing procedure. This includes the 
reporting of adverse events, a process often dependant on spontaneous 
reporting of the events by health care providers. The driving force behind the 
FDA guidance documents is to identify potential risk to those being treated.  
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Because of the basic care provided, barriers to communication and generally 
weaker disease surveillance systems, pharmacovigilance in Africa lags 
behind Europe and the US. It will therefore be necessary to adapt the 
methods of strong pharmacovigilance to a field applicable standard to 
improve overall surveillance. A Pubmed search found 1423 articles related to 
pharmacovigilance but only 29 articles for pharmacovigilance and Africa; of 
those 10 are related to malaria and 5 are overviews of suspected adverse 
events related to veterinary drugs in South Africa. There were no articles on 
Human African trypanosomiasis and pharmacovigilance. Despite the fact that 
there is not much of a history of pharmacovigilance in Africa, there are 
lessons that can be learned. The experiences of the Mectizan Donation 
Program detailing serious adverse events related to the use of ivermectin for 
the treatment of onchocerciasis (Twum-Danso 2003) can be a guide and offer 
hope.  
Although there are barriers to implementing pharmacovigilance in Africa, 
certain aspects of HAT distribution and drug use may be advantageous such 
as the fact that the medication is donated to the World Health Organization, 
the number of cases are relatively low, the drugs are distributed through 
country programs to a limited number of facilities and there are a limited 
number of countries involved. One challenge to pharmacovigilance in 
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developing countries has been the lack of infrastructure and commitment of 
the pharmaceutical industry. Having the WHO and Ministries of Health take 
the lead investigative role will help alleviate this problem. 
 
Approaches for collecting HAT 
pharmacoepidemiology/pharmacovigilance data 
 
What data to collect 
To start, it is necessary to determine what information will be collected. Will 
the system focus on stage I, stage II or both? Due to the nonspecific and 
intermittent symptoms associated with stage I, the majority of patients have 
stage II at the time of diagnosis(Odiit, Coleman et al. 2005). When this fact is 
combined with the current lack of resources for the active population 
screening necessary to find stage I patients in large numbers, we propose that 
the data collected be for drugs used to treat stage II disease. The system 
should be flexible enough to incorporate new regimens as they are 
introduced. 
The next question is one not unique to HAT; will the pharmacovigilance 
system look for adverse events (AEs), adverse drug reactions (ADRs) or a 
combination?  In this case we will use the WHO definitions for both 
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terms(WHO 2002). An AE is described as “any untoward medical occurrence 
that may appear during treatment with a pharmaceutical product but which 
does not necessarily have a causal relationship with the treatment.” An ADR 
is “a response to a drug which is noxious and unintended, and which occurs 
at doses normally used in man for the prophylaxis, diagnosis, or therapy of 
disease, or for the modification of physiological function.” 
There are several types of ADRs already associated with HAT treatment 
including encephalopathic syndromes(Blum, Nkunku et al. 2001), skin 
reactions, anemia and leucopenia(Milord, Pepin et al. 1992). We recommend 
that all ADRs be recorded and reported, especially because new regimens and 
drug combinations are being introduced. In addition to ADRs, drug 
utilization should be examined. Stage II treatment is administered as inpatient 
care. Several of the medications are given parenterally so injection site 
infections are a concern and should also be reported.  
As noted previously, in certain foci melarsoprol has become less effective 
prompting a switch to eflornithine(Moore 2005). Due to this phenomenon, 
treatment failures should also be monitored by the 
pharmacovigilance/pharmacoepidemiologic mechanism. Determining an 
accurate denominator for treatment failures is vital and therefore all stage II 
patients need to be monitored, not solely those failing treatment. 
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The system should not be overwhelmed by adverse events and yet there is a 
need to address reporting of unexpected as well as expected AEs. An expert 
committee could meet at the ISCTRC conference or at a WHO summit to 
determine the AE list and the severity level at which events would trigger a 
response. 
 
Reporting methods and channels 
A method of reporting will need to be established. The goals of CDC‟s 
Morbidity and Mortality Weekly Report (MMWR) Surveillance 
Guidelines(1988) to give credible, accurate, timely and useful scientific 
information can also be applied here; the system should also be simple and 
flexible.  
The two main reporting approaches are passive surveillance such as 
spontaneous reporting and more active pharmacoepidemiologic methods (US 
Health and Human Services 2005; Talisuna, Staedke et al. 2006; ISPE 2007). 
Both methods can serve as useful tools in assessing drug safety.  Spontaneous 
reporting can be useful in finding rare adverse events that were not seen 
during clinical trials(Ineke Neutel and Walop 2000). Spontaneous reporting 
is dependent on the people detecting the events and therefore there is a 
potential for under-reporting and differences between sites which could lead 
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to varying levels of sensitivity. There are several major challenges to 
reporting in order to avoid biased or incorrect reporting. To address these 
issues will require training at the national level, onsite tutoring at the local 
level and data checks/quality control at all levels.  
 
The biological and geographical challenges associated with the control of 
sleeping sickness point to a pharmacovigilance approach best addressed 
through the use of both passive and active reporting methods.  
 
Active surveillance would require that programs seek out cases and AEs. 
This could be implemented through intensive reviews of hospital records at 
sentinel sites. The active surveillance is an area the sensitivity of the system 
would be tested and ideally validated. A pharmacovigilance system, by 
collecting demographic data, is more than counting AEs but is also a method 
to suggest which persons or groups may be at a higher risk for developing an 
AE.  Using active surveillance can provide data to allow for 
pharmacoepidemiologic studies. 
 
Two potential approaches for using pharmacoepidemiology in the field 
would be the implementation of case control and cohort studies. Case control 
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studies are frequently used when adverse events are first detected in order to 
determine potential exposures that could have led to the adverse event. This 
can be appropriate and is a relatively inexpensive and quick approach once 
the events have been detected. Cohort studies follow patients prospectively in 
order to see if an event will take place. This can be expensive and the sample 
size potentially would have to be large in order to detect rare adverse events.  
 
The fact that all medication is channeled through WHO allows for an 
accurate denominator in regards to the number of treatments provided; in 
theory this could also be a way to get a rough count how many patients were 
treated but in reality this would not be optimal since it would not account for 
expired medication or unused treatments. To address this, treatment data 
from the centers would still be critical. The problem is the speed in which 
these data are reported back to the MOHs from the treatment centers and how 
quickly the MOHs transmit the information to WHO.  Sentinel sites would 
allow for detection at a more rapid pace. The sites would report the 
information simultaneously to WHO and the MOH. A critique of using 
sentinel sites is that there is potential for selection bias but in situations where 
drugs are exclusively administered in a health care setting, they can be 
effective tools for pharmacovigilance(WHO 2002). 
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Sentinel sites would be the ideal location to set up cohort studies discussed 
previously. The sites would allow for in-depth pharmacoepidemologic study 
and would be active in surveillance. Selection of sites should be weighted so 
that the countries with the greatest burden (DRC, Angola and Sudan) are 
represented. Currently those three countries account for more than 87% of 
global cases(Simarro, Jannin et al. 2008). 
 
 
An example of what a PV/PE system for HAT would look like 
The following approach could help in the goal of establishing 
pharmacovigilance for HAT. A simple and secure website managed by WHO 
could be used to enter the adverse events. These data would be collected at 
the Ministry of Health level through a National Pharmacovigilance 
Center(WHO 2002) and then uploaded for compilation, analysis and 
dissemination. If a country feels it can not create a dedicated Center, the 
section of the MOH charged with HAT control could still take on the role of 
“collecting and analyzing case reports of ADRs”(WHO 2002). The proposed 
routes for communication are illustrated in Figure 1. It is recommended that 
data flows from the health centers to the Ministries to WHO and back but 
that there should be mechanisms for WHO to contact the health centers 
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directly for quality control. This would be necessary for the sentinel 
surveillance sites.  
 
  
WHO
MOH
PV Center
Health 
Center
 
Figure 1 
Communication channels for reporting HAT pharmacovigilance  
 
The necessity for inpatient care assures that self-medication is not an issue 
for HAT as well as a reduced risk for under dosing. There is no commercial 
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market for the drugs unlike the situation for malaria(Talisuna, Staedke et al. 
2006). These are some positive points that will make HAT 
pharmacovigilance more feasible though still with plenty of challenges.  
 
To address these challenges additional measures will need to be tackled. 
Tools that can be of help to the WHO and the MOHs are to use maps of old 
foci to identify areas potentially at risk for cases(Chappuis, Loutan et al. 
2005). Reporting of pharmacoevents via cell phones is another rapid and 
inexpensive tool that should be used. In countries with few cases, adapting 
methods from the Guinea Worm Elimination Program approach of 
identifying every case and follow them through successful treatment would 
be a preferred approach(Ruiz-Tiben and Hopkins 2006). Once a reporting 
system and standard is established there will need to be capacity building to 
ensure that the methods are applied correctly(WHO 2002; US Health and 
Human Services 2005). 
Spontaneous reporting will still be encouraged, necessary and one of the 
primary methods for detecting ADRs. These events should be reported to the 
MOH. If the mechanism for sentinel surveillance has been established, sites 
not included in the sentinel network would be encouraged to report to the 
MOH Pharmacovigilance Center. If the network had not been established, 
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those observing the ADRs would report to their district HAT contact person 
who would then report to the MOH. This is possible since all medication is 
delivered through a central WHO/MOH mechanism. In centers run by NGOs 
they would be advised/required to report to the WHO/MOH contact as part of 
their responsibility to receive medication. 
A key to any successful reporting system will be its ease of use. Reporting 
that is too complicated or redundant will lead to errors. National 
Pharmacovigilance Centers, as advocated by WHO(WHO 2002), can help 
address these problems by having a level of expertise and capacity building 
potential. Having a central location to report to would also help avoid 
confusion and the loss of data. The central location also makes sense since 
the medication all flows through the national programs; to run a parallel or 
decentralized reporting system would just add unnecessary levels of 
paperwork and bureaucracy.  In the Democratic Republic of The Congo, 
there is currently a project in tandem with the Institute of Tropical Medicine 
in Antwerp that is attempting to improve pharmacovigilance for HAT 
treatment [personal communication]. The overall goals to improve 
surveillance are to be lauded however the methods to create a decentralized 
system do not seem to be in line with the goals established by the WHO. In 
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order to have a methodology, standards and results that can be compared 
between countries we advocate following WHO‟s approach.  
 
 
Summary 
There are many challenges to establishing a reliable pharmacovigilance 
network. These are not issues limited to the African setting are common in 
resource limited situations often resulting in the lack of infrastructure and 
difficult work environment. These challenges do not mean that 
pharmacovigilance is not possible in Africa or should be set to a lower 
standard. In the case of human African trypanosomiasis we argue that the 
most rigorous approaches advocated by WHO and the FDA should be 
embraced(WHO 2002; US Health and Human Services 2005).  WHO and the 
international community should be realistic about the challenges and 
understand that building new mechanisms will take time and new 
approaches.  
The increased use of eflornithine and possibly eflornithine/nifurtimox 
combination therapy will offer alternatives to melarsoprol for the treatment 
of T. b. gambiense associated HAT. These therapies have the potential to be 
safer with fewer adverse events but much is still unknown. Additionally there 
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are new drugs in the pipeline and the system has to be flexible to 
accommodate them. Improving pharmacovigilance at same time these 
medications are being introduced or given expanded use is an opportunity 
that should not be missed. 
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Chapter 7 
 
 
Summary and discussion 
 
The epidemiology of Human African Trypanosomiasis (HAT) can be used as 
a guide to highlight the dangers of complacence and the neglect given to 
tropical diseases.  The disease which had been a major public health problem 
at the start of the 20
th
 century had been successfully controlled and was no 
longer a priority for the international health community or the leaders of the 
newly independent countries where the disease is endemic(Burri and Brun 
2003; Simarro, Jannin et al. 2008). The neglect of the disease allowed it to 
fester in remote areas of Africa(Legros, Fournier et al. 1999; Stanghellini and 
Josenando 2001; Van Nieuwenhove, Betu-Ku-Mesu et al. 2001), building a 
reservoir that allowed for a dramatic resurgence of the disease at the end of 
the 20
th
 century that approached the levels seen at the start of the century. 
There was a recognition by WHO, the endemic countries and others in the 
international health field that a concerted effort must be made to control the 
disease once again(WHO 1998; Cattand, Jannin et al. 2001). 
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Surveillance for HAT treatment failure 
 
One key issue that allowed for the resurgence to gain traction was the overall 
weakness of the surveillance systems(WHO 1998). Countries did not 
communicate with WHO or their neighbors, there were different definitions 
of the disease, civil conflicts isolated regions and slowed the distribution of 
medicine(Berrang Ford 2007), and poor infrastructure combined with a lack 
of resources did not allow for the detection and communication necessary to 
have surveillance that was effective and efficient(Shaw 1989; CDC 1999).  
It was in this context that another disturbing issue was discovered, elevated 
melarsoprol treatment failure(Pepin and Mpia 2005). HAT is a neglected 
disease that has a number of challenges to face for successful control and one 
of the greatest barriers is the lack of treatment options(Molyneux 2004). 
There are currently only four drugs licensed for the treatment of HAT, with 
melarsoprol having been the most important for the treatment of the more 
severe meningo-encephalitic stage of the disease (stage II)(Croft, Barrett et 
al. 2005). The drug, though toxic, had worked successfully since its 
introduction in 1949(Friedheim 1974). This began to change in the late 
1990‟s when patients treated for T.b. gambiense in several areas of Angola, 
Sudan and Uganda (Moore, Richer et al. 1999; Brun, Schumacher et al. 2001; 
Matovu, Enyaru et al. 2001)began to fail melarsoprol at levels much higher 
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than the historical rate of 5-8%. As the disease is fatal left untreated, the loss 
of the most important chemotherapy could have devastating consequences 
(Burri and Keiser 2001; Fevre, Picozzi et al. 2006).  
The overall poor surveillance system combined with a new phenomenon of 
treatment failures led to the creation of a sentinel surveillance based study to 
examine the issue and to get a better understanding of the geographic and 
epidemiologic scope of the problem. This study was called HATSENTINEL. 
To successfully implement this study a standard approach to surveillance had 
to be taken in order to have data that was comparable between countries. A 
standardized questionnaire, case definitions and study protocol allowed for 
this and was used in this study.  
The HATSENTINEL study began in July 2002 and eventually comprised 9 
sentinel sites in 5 countries collecting data on all stage II patients (see the 
dissertation chapters 1 and 2 for a more detailed description). Seven of the 
sites were in areas endemic for T.b. gambiense and two were in regions with 
T.b. rhodesiense. We did not find elevated treatment failure issues at the T.b. 
rhodesiense sites and the remainder of the discussion will focus on the results 
from the sites monitoring T.b. gambiense.  
The study detected a focus in the East Kasai province of the Democratic 
Republic of The Congo (DRC) that was previously unknown to have 
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melarsoprol treatment failure problems. The sentinel sites in Katanda, DRC 
and Mbuji Mayi, DRC had melarsoprol failure rates of 62% and 55% 
respectively and were unexpected results. Treatment failures at the site in 
northern Angola in M‟banza Congo had been previously detected but not at 
the levels we found, with 98% of patients not responding to melarsoprol. The 
elevated failure levels detected by HATSENTINEL when contrasted to the 
historical rates of 5-8% led the Ministries of Health in the DRC and Angola 
to switch their first line therapy for stage II disease to eflornithine. 
The longitudinal and flexible design of the HATSENTINEL study allowed 
for us to accommodate such changes in therapy and continue analyzing 
results from the data collected.  
Two of the sentinel sites for the study (Sudan and Caxito, Angola) were 
using eflornithine to treat second stage disease from the debut of 
HATSENTINEL. By including data from the three sites that switched to 
eflornithine, we were able to demonstrate and replicate the positive results 
that has previously described. Melarsoprol treatment failure rates that had 
ranged from 55-98% fell to 2-4% for patients treated with eflornithine. This 
led to decreases in the number of patients seeking retreatment, reducing the 
overall caseload by as much as 40%.  
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The results from the eflornithine treatment data are encouraging and will be 
of interest to national programs, possibly accelerating the calls for a full-scale 
switch for first line usage (Chappuis, Udayraj et al. 2005; Balasegaram, 
Young et al. 2009). This could be the right approach but should be taken with 
caution and the understanding that surveillance will need to be continued and 
actually strengthened. Melarsoprol will continue to be a necessary drug as it 
is the only treatment option for T.b. rhodesiense patients and will be used for 
T.b. gambiense patients who do not respond to eflornithine. 
 
Lessons learned from implementing HATNSENTINEL 
 
Both care and record-keeping are basic in the facilities where HAT is treated, 
and formal surveillance for treatment failure had not previously been 
attempted.  However, once implemented, the system worked well.  
Acceptability of the surveillance system by the facilities was high and data 
quality remained high throughout the 6 year surveillance period.  The country 
programs were able to use the data for decision-making and changing policy. 
This demonstrates how HATSENTINEL met the criteria(MMWR 1988) for a 
successful surveillance system by being simple and flexible while able to 
give credible, accurate, timely and useful scientific information.  
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 An additional observation from the HATSENTINEL data could have 
implications for future clinical trials(WHO 2007). The current 
recommendations are to follow patients for 24 months after treatment to 
assure that they are disease free. Data from the two largest sites in the 
HATSENTINEL network showed that the majority of patients who fail 
treatment do so in the first 18 months. By extending the data collection to the 
full 24 months we detected an additional 6.5% of treatment failures for 
melarsoprol. This raises the question of what advantages or disadvantages 
would arise if the follow-up period was reduced to 18 months.  
 
Pharmacovigilance 
 
Future efforts to control HAT should incorporate pharmacovigilance. 
Compared to other infections, clinical trials for HAT enroll a limited number 
of patients. This is due the logistical difficulties of conducting the clinical 
trials in settings with shrinking patient populations. New regimens or drugs 
are likely to be introduced with less data than for other diseases and 
therefore, surveillance will be important to assess drug safety and efficacy.   
Expanded use of eflornithine for the treatment of second stage disease is 
underway and being advocated(Chappuis 2007). A combination therapy of 
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nifurtimox-eflornithine(Priotto, Kasparian et al. 2007) looks like an 
additional promising treatment option.  
There is considerably less experience with eflornithine(Burri and Brun 2003) 
than with melarsoprol and this can raise questions about its long-term 
efficacy. To address these questions surveillance must continue and the 
adoption of a pharmacovigilance approach should be considered(WHO 2002; 
WHO 2004). 
The situation for HAT therapy is somewhat unique in that all medication is 
funneled through WHO to the Ministries of Health. This allows for a level of 
control of the drug supply and the potential for accurate data collection. The 
countries do suffer from a lack of infrastructure that is needed for strong 
surveillance however this should not lead to avoiding the creation of a 
pharmacovigilance system(Talisuna, Staedke et al. 2006). The limited 
number of cases and the control of the medication can be used as an 
opportunity to create such a network and to tailor it to the needs of the 
Human African Trypanosomiasis community. Through the collection of data 
according to international standards, programs will be better able to address 
potential future challenges to the chemotherapy of the disease. This data will 
also be necessary if new drugs are to be developed and if clinical trials are to 
be implemented(WHO 2007). 
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Unanswered research questions and recommendations 
 
More research is needed on several fronts including the cause of treatment 
failure and the future direction of pharmacovigilance. 
The cause of melarsoprol failures is still unknown. This should be examined 
further.  
Technical issues hampered the propagation of trypanosome specimens 
collected at the sentinel sites. Improving methods of isolation and 
propagation in an effort to minimize clonal selection should be a priority. 
Improving tools for molecular epidemiology with the ability to compare 
strains and correlate those strains with clinical results would allow for foci 
specific treatment and control measures.   
In vivo melarsoprol sensitivity testing on a limited number of specimens did 
not show resistance to the drug.  
More studies need to be done in order to determine risk factors for treatment 
failure, with a special emphasis on host immune status.  
Continued surveillance and the implementation and concrete development of 
a pharmacovigilance system should be a priority. There should be an 
expansion of the number of facilities in any future surveillance network. 
Calls from the WHO and the heads of African states for the elimination of 
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the disease make the need for the data collected with a strong surveillance 
system even more timely.  
There should be the development of a second generation of treatment failure 
tools that allowed for surveillance of stage I drugs and the flexibility to 
collect data on new drugs and treatment regimens.  
There should also be an emphasis on surveillance capacity building in the 
countries suffering from HAT. This would allow for faster and more 
effective data sharing. 
The expanded use of eflornithine and nifurtimox-eflornithine combination 
therapy offer hope for the reduction of this disease. At the same time, this 
should be approached cautiously and viewed in the historical context so that 
progress made towards the reduction of cases is sustainable. Through 
continued surveillance, timely data will be available for making public health 
decisions. 
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 Appendix : HATSENTINEL TREATMENT CENTER FORM 
 
facility name: _____________________________________________  
facility location:______________  _____________________________  __________ 
   country          province  county town/village 
 
geographical  coordinates:      N/S: ___
o
__’__’’   E/W: ___
o
__’__’’     (GIS    map) 
 
catchment area:______sq km  ______population  (estimated   census data; year____) 
 
facility  hospital  administration:  government      patient capacity: ___no. beds    
 type:    health center      private         ____no.  mats 
   other    NGO     ___ no. other 
       joint  __no.  total 
       other 
 
.    DISEASE PREVALENCE IN CENTER CATCHMENT AREA 
 
sleeping sickness ____% ( estimated      data-based        prevalence unknown) 
malaria (peak season) ____% ( estimated      data-based        prevalence 
unknown) 
malnutrition  ____% ( estimated      data-based        prevalence 
unknown) 
HIV   ____% ( estimated      data-based        prevalence 
unknown) 
other___________ ____% ( estimated      data-based        prevalence unknown) 
.                     PATIENTS TREATED IN CENTER      
    
                   2002       2001 2000 
number of patients treated, total (all conditions)______________________________ 
 
number of patients treated, sleeping sickness _________ ___________________ 
 number stage I    __________________________ 
 number stage II    ___________________________ 
 case detection: number active  ___________________________ 
    number passive  __________________ 
 mortality:  % stage I  ___________________% 
    % stage II  ___________% ___% 
.                      
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TRYPANOSOMIASIS DIAGNOSIS 
 method   frequency of use 
      routine  occasional         never unknown 
serology CATT             
CATT with serum dilutions         
IFAT              
other (_________________)           
  
trypanosomes, microscopy, lymph node       
 peripheral, microscopy, blood(wet/stained)       
microscopy, buffy coat           
QBC             
anion exchange column           
other (_________________)           
   
staging, CSF trypanosomes, no centrifugation        
examination trypanosomes, double centrifugation       
WBC          
Protein              
IgM             
other (______________________)          
.   DRUG THERAPY USED IN THIS CENTER 
    as first  as alter- not   
    line    native  used  dose  duration  
STAGE I 
pentamidine     ___.__ (mg/kg/d)       x____ days 
suramin      ___.__ (grams/dose)  x __ doses 
 
 
 
STAGE II 
pentamidine, pretreatment     ___.__ (mg/kg/d)  x_____days 
suramin, pretreatment     ___.__  (grams/dose)  x___ doses 
melarsoprol, with rest periods    see schedule below 
melarsoprol, no rest periods    ___.__ (mg/kg/d)        
nifurtimox monotherapy     ___.__ (mg/kg/d)      x ___ days 
DFMO monotherapy     ___.__(mg/kg/d)      x  days 
combination therapy   
 melarsoprol/DFMO      see schedule below 
 melarsoprol/nifurtimox      see schedule below 
 DFMO/nifurtimox      see schedule below 
other (________________)          ___.__ (mg/kg/d)       x  ___ days 
.      MELARSOPROL ADMINISTRATION AT THIS CENTER 
 
  DOSING (mg/kg)         
  Injection     1     2     3    4    5     6   7   
 1 2 3 4   8     9   10   11   12   13 14 
series 1 _____ _____ _____ __ 15   16   17   18   19   20   21 
series 2  _____ _____ _____ _____ 22   23   24   25   26   27   28 
series 3 _____ _____ _____ _____  29   30   31   32   33   34   35  
series 4  _____ _____ _____ _____ 36   37   38   39   40   41   42 
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mark days of drug administration on chart at left with X 
  .                    COMBINATION THERAPY FOR STAGE II TRYPANOSOMIASIS  
 
MELARSOPROL/NIFURTIMOX 
 melarsoprol dose:      constant dose _______mg/kg/d      1     2     3    4      5     6     7 
   increasing dose, as shown above          8     9   10   11   12   13   14 
   other (specify)_______________              15   16   17   18   19   20   21 
 nifurtimox dose:    __________ mg/kg/d       22   23   24   25   26   27   28 
           29   30   31   32   33   34   35 
 mark days of  administration of melarsoprol with X            36   37   38   39   40   41   42 
 and days of nifurtimox with O  in chart at left 
 
 
MELARSOPROL/DFMO 
 melarsoprol dose:  constant dose              mg/kg/d            1     2     3    4      5     6     7 
   increasing dose, as shown above           8     9   10   11   12   13   14 
   other (specify)_______________             15   16   17   18   19   20   21 
 DFMO  dose:                              mg/kg/d        22   23   24   25   26   27  28 
                                                                                                       29   30   31   32   33   34   35 
 mark days of  administration of melarsoprol with X            36   37   38   39   40   41   42 
 and days of DFMO with O  in chart at left 
 
DFMO + NIFURTIMOX 
 DFMO dose:    __________ mg/kg/d  x  _______ days 
 Nifurtimox dose:  __________ mg/kg/d  x ________days 
 
 
 
 
  . CRITERIA USED TO DEFINE TREATMENT FAILURE OR RELAPSE  
 
used not used unknown  
            trypanosomes identified in CSF 
 
           CSF WBC >50  (or >____ specify alternative WBC cut-off value) 
 
            CSF WBC > 5  (or >____specify alternative cut-off) AND an increase from 
previous  exam of more than ____% (specify)) 
 
            does not meet criteria above, but clinical symptoms strongly suggest relapse 
in the absence of other diagnosis 
 
            other (specify:                                                                                     ) 
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.            THERAPY OF TRYPANOSOMIASIS AFTER RELAPSE 
 
therapy         relapse 1  relapse 2          relapse>2 
 
     first line alternative first line alternative first line alternative 
melarsoprol, with rest periods                            
melarsoprol, no rest periods           
nifurtimox monotherapy           
DFMO monotherapy           
combination therapy   
 melarsoprol/DFMO                               
 melarsoprol/nifurtimox                   
 DFMO/nifurtimox            
other (________________)              
          OTHER THERAPY PROVIDED ROUTINELY FOR TRYPANOSOMIASIS PATIENTS 
 
           therapy  frequency of use 
 
   routine  when indicated seldom never 
                     by exam 
prednisolone pretreatment                 
       (dose: __________ mg/kg/d or  mg/d)  
prednisolone during melarsoprol therapy                 
       (dose: __________ mg/kg/d or  mg/d) 
multivitamin pretreatment                    
antimalarial pretreatment                   
antiparasitic pretreatment for intestinal helminths                  
antibacterial agent, pretreatment                   
antibacterial agent during melarsoprol therapy                
 
 
 
 
    FOLLOW-UP OF PATIENTS TREATED AT THIS CENTER 
 
LP performed immediately post treatment:        yes       no 
mean duration between treatment and 1st follow-up exam:__months(estimated  calculated) 
 
mean number of follow-up exams per patient in a 2-year post treatment period: ___exams 
      ( estimated    calculated) 
proportion of treated patients with at least one follow-up exam: ____% 
 
date of form completion:    ____/_____/____ (dd/mm/yy) 
 
form completed by:   name_______________________     
position______________________________ 
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         HATSENTINEL 
    TREATMENT CENTER UPDATE FORM 
facility name________________________________________________  
facility location: ______________    _______________    __________________________ 
     country           province county  town/village  
 
time period covered by this report:  from __/__/__  to __/__/__ (dd/mm/yy) 
 
      PATIENTS TREATED IN CENTER  
                   this interval       year to date 
                 (__/__/__ to __/__/__)  
 
number of patients treated, sleeping sickness total ________ ___________ 
 number stage I    _______________ 
 
 number stage II, total   ____________ ___________ 
   
 number stage II not previously treated ____________ ___________ 
   
  number stage II previously treated for stage I _____________________ 
  number stage II previously treated for stage II ____________ ___________ 
 
case detection: number active  ___________ ___________ 
                    number passive  ___________ ___________ 
mortality: % stage I  ___________% ___________% 
   % stage II  ___________%___% 
number of follow-up exams performed: ___________ ________ 
 
recent changes in diagnosis or treatment practices in this facility:   yes      no     
unknown 
   (if yes, note changes on center information form) 
 
date of completion of this form :    ____/_____/____ (dd/mm/yy) 
 
form completed by:   name_________________position___________________________ 
 
Comments:  
______________________________________________________________________________________
______________________________________________________________________________________
_________________________________________________________________________________     
______________________________________________________________________________________
____________________________________________________________________ 
________________________________________________________________
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 Appendix : HATSENTINEL CASE REPORT FORM 
 
REPORTING FACILITY 
facility name: __________________________________________            facility 
code:___________ 
facility location: ____________________      _________________________________ 
country       town/village 
 
form completed by:   name_____________________________          
position________________________ 
PATIENT DATA 
patient identification number: ______    age:____(years) 
signed consent for medical record release:   sex:   male     female     unknown 
 
residence location: _____________      ___________ _____________________________ 
   country province  county     town/village 
 
 
SPECIMEN COLLECTION 
specimen(s) collected/stored for this patient?     yes      no        unknown 
 
facility name: ______________  specimen handled by: name____________________ 
 
facility code : __________________           position 
___________________ 
informed consent obtained: yes    no   patient ID number:______________ 
 
 
DIAGNOSIS AND STAGING 
initial diagnosis of sleeping sickness (date: ___/___/___ (dd/mm/yy)) 
parasitologic confirmation:  confirmed    (  lymph node fluid     blood      CSF     
unknown) 
(check all that apply)  not confirmed   
       Was the patient previously treated for 
sleeping sickness? 
yes       no        unknown 
(If yes, complete the following) 
 CSF examination for 
CURRENT 
ADMISSION 
CSF examination at the 
time of initial diagnosis   
CSF 
examination 
(most recent 
exam prior to 
current 
admission) 
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Date   
(dd/mm/yy)       
 
___/____/____ 
 
___/____/____ 
 
___/____/____ 
 
Trypanosomes:    
     yes    
     no    
     unknown    
WBC:    
     cell count Cells 
_____________ 
Cells _____________ Cells 
_____________ 
     unknown    
IgM    
     titer > 1 titer > 1:______ titer > 1:______ titer > 
1:______  
     not done    
     unknown    
 
PREVIOUS THERAPY 
(Complete this section if patient has been treated for stage I or stage II sleeping sickness in the 
past.  
           Skip to Current Therapy if this report covers the patient’s first 
treatment.) 
 
previous therapy for stage I :  yes ( treatment drug:   pentamidine     suramin    
 unknown) 
(check all that apply)      no 
 
number of previous treatments for stage II :    0       1        2         3      > 4         
unknown 
 
 Treatment 1 Treatment 2 Treatment 3 
Date  
(dd/mm/yy)       
 
___/____/____ 
 
___/____/____ 
 
___/____/____ 
Treatment Type 
(check all that apply)  
   
  mel (with rest 
periods) 
   
  mel (no rest periods)    
  nifurtimox alone    
  DFMO alone    
  DFMO + nifurtimox     
  melarsoprol + DFMO    
  melarsoprol + 
nifurtimox 
   
  other/unknown    
Therapy duration 
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  full    
  incomplete    
  unknown    
 
 
       CURRENT THERAPY 
 
for patients previously treated for stage II trypanosomiasis  (check all that apply) 
decision to re-treat based on:  CSF tryps        CSF WBC         CSF IgM           clinical 
exam     
       other (________________________) 
 
for all patients with stage II trypanosomiasis   treatment start date 
__/__/__ 
 
trypanosomiasis treatment:  therapy duration:    other drug administered: 
 melarsoprol, with rest periods   full course    prednisolone  
 melarsoprol, no rest periods  incomplete course    antimalarial agent  
 DFMO monotherapy   unknown   antibacterial agent 
 DFMO + nifurtimox     other 
 melarsoprol + DFMO        unknown 
 melarsoprol + nifurtimox   
 other (_______________________)   
 
 
clinical status at admission:   symptomatic       asymptomatic 
clinical status at discharge:    clinical improvement       no improvement      death   
    unknown 
CSF examination post treatment:  not done 
        done---results:   trypanosomes:   yes       no 
                       WBC _______cells  
 
Comment:  ___________________________________________________________________________ 
______________________________________________________________________________________
___________________________________________________________     
______________________________________________________________________________________
____________________________________________________________________ 
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